As part of the French delegation, alongside Business France Healthcare North America, ETAP‑LAB will take part in BIO Partnering™, the reference platform for one‑to‑one business meetings during the event.

👉 Learn more about the event: https://convention.bio.org/

Where innovation meets decision-making

The BIO International Convention is not just a scientific conference — it is where strategic decisions are made.

Over four days, biotech startups, pharma leaders, CROs, and investors gather to:

• initiate partnerships
• accelerate R&D programs
• secure funding and licensing deals
• move innovative therapies toward patients

For companies navigating the complexity of drug development, BIO is a unique opportunity to connect directly with the right partners at the right time. Meet ETAP-LAB this time!

Why meet ETAP‑LAB at BIO 2026?

At ETAP‑LAB, our objective at BIO is clear: help you move your therapeutic innovations forward with confidence.

We support all types of preclinical-stage projects, from early discovery to advanced translational studies, including  in vitro lead optimization to non-GLP animal testing (POC studies, PK/PD modeling and non-regulatory safety pharmacology).

Whatever your range of therapeutic innovation: small molecules, antibodies & biotherapies, cell therapies, medical devices and nutraceuticals.

What you gain by meeting us

Whether you are:

• preparing an IND
• validating a candidate before fundraising
• or facing key go/no‑go decisions

We provide advice and expert services:

• robust, decision‑enabling data with high translational relevance
• optimized study designs to reduce experimental and regulatory risks
• fast, responsive support adapted to your timelines
• end-to-end capabilities, from in vitro to in vivo and advanced analyses

From early discovery to in vivo validation: a fully integrated approach

One of ETAP‑LAB’s key strengths lies in its transversal expertise.

For example, in neurodegenerative diseases such as Alzheimer’s:

• start with high‑content in vitro screening (human iPSC-derived models, primary cells)
• refine candidate selection with multiparametric analyses
• progress seamlessly toward in vivo studies, including advanced behavioral pharmacology
• complete your program with integrated biological analyses (e.g. immunohistochemistry)

Result: A consistent, reliable data package to support your development milestones and investor discussions.

New structure, clearer offer: discover our 4 specialized brands

BIO 2026 will also be the opportunity to introduce our new brand architecture and website.

To improve clarity and enhance your experience, we have organized our expertise into four dedicated service brands:

• BRAINXPLORE — Neurology / CNS
• SKINAXIS — Dermatology
• STROK@LLIANCE — Neurovascular / Stroke
• SYNCROSOME — Cardiology

All under one unified entity, ETAP‑LAB, as a trusted & renowned preclinical CRO.

What’s new for you

• clearer service positioning by therapeutic area
• easier navigation across our portfolio of models and technologies
• faster access to expert teams
• a more intuitive and efficient customer journey

Explore our new website now: https://www.etap-lab.com/en/

Meet us through BIO Partnering™

ETAP‑LAB will be available exclusively through BIO Partnering™ one‑to‑one meetings, and also at the French Pavilion.

👤 Nicolas Violle, CEO, will be on-site to discuss your projects.

You should meet us if you have an ongoing preclinical program and need a trusted CRO partner with strong scientific expertise.

📅 Request a meeting directly via the partnering platform (https://convention.bio.org/) or through our website (https://www.etap-lab.com/en/contact/).

Supported by our ecosystem

ETAP‑LAB’s participation in BIO 2026 is supported by:

• Eurobiomed, through its international development program, and the Région Sud Provence-Alpes-Côte d’Azur, providing financial support.
• Business France Healthcare North America, as part of the French delegation

This backing reflects the recognition of ETAP‑LAB’s expertise and its ambition to expand internationally.

Let’s accelerate your preclinical development

At BIO 2026, our goal is simple: help you reduce uncertainty, gain clarity, and move faster toward clinical development.  We look forward to meeting you in San Diego.

In the meantime, feel free to subscribe to our NEW newsletter, which will be released in June 2026!

L’article BIO Convention 2026: meet ETAP‑LAB in San Diego est apparu en premier sur ETAP-LAB.

In a context where societal expectations, regulatory frameworks, and scientific standards are rapidly evolving, organizations like ETAP-LAB play a critical role in balancing therapeutic innovation, scientific rigor, and ethical responsibility.

“Ethology has been at the core of our practices for over 35 years.” — Nicolas Violle, CEO, ETAP-LAB

A Science-Driven and Responsible Approach to Preclinical Models

In this interview, ETAP-LAB shares its vision of responsible research, particularly in the use of rodent models in neurology (including stroke), cardiology, and dermatology.

The company is actively committed to:

• integrating animal welfare into scientific quality
• rigorously applying the principles of the 3Rs (Replace, Reduce, Refine)
• developing innovative R&D programs aimed at reducing and replacing animal models

Accelerating the Shift Toward Alternative Methods

ETAP-LAB is also engaged in advancing and implementing alternative approaches, including New Approach Methodologies (NAMs) and organ-on-chip technologies, which are expected to play an increasing role in the future of biomedical research.

While these methods are progressing, their broader adoption still depends on validation and regulatory acceptance.

The challenge is two fold:

• accelerate the development and recognition of alternatives
• while continuously improving practices when animal models remain necessary

The Strategic Role of CROs in the Evolving Landscape

This interview highlights the pivotal role of CROs in drug development, at the intersection of academic research, the pharmaceutical industry, and regulatory requirements.

It also emphasizes the importance of transparency and public dialogue—key missions of Gircor.

Read the Full Interview

To learn more and explore the full discussion (French version only):

🎙️Les défis d’une CRO dans l’évaluation préclinique du médicament

Get in Touch

Interested in learning more about our approaches, models, or R&D programs?

Contact the ETAP-LAB team to discuss your projects.

L’article The Challenges of a CRO in Preclinical Drug Development: ETAP-LAB Featured in Gircor News est apparu en premier sur ETAP-LAB.

Key points:

• A new ETAP-LAB brand identity, asserting its values of Excellence, Transparency, Agility, and Proximity.
• A clarified brand architecture, with ETAP-LAB as the umbrella brand.
• Restructuring of the offering around four Service brands, each dedicated to a specific preclinical area of expertise: BRAINXPLORE, SKINAXIS, STROK@LLIANCE, and SYNCROSOME.
• Launch of a new website on April 29, 2026 (www.etap-lab.com/en), merging three existing sites.

Clarifying the Offering to Better Address Preclinical Challenges

With the growing trend toward outsourcing R&D activities, preclinical CROs play a strategic role in supporting pharmaceutical companies by de-risking their molecule pipelines, winning over investors and partners, and meeting the requirements of drug regulatory agencies.

Driven by sustained growth over the past 10 years—notably with the creation of STROK@LLIANCE in 2017 and the acquisition of the CRO SYNCROSOME in 2023—ETAP-LAB has expanded and strengthened its activities. This evolution has highlighted the need to better showcase its established and emerging expertise and make its offering more transparent.

Four Service Brands, One Scientific Standard

To better meet the needs of its market, ETAP-LAB has decided to adopt an umbrella brand structure, bringing all of its activities together under a single, recognized entity, while organizing its offerings around four Service brands, each representing a clearly defined area of preclinical expertise.

These include two long-standing and well-established brands:

• STROK@LLIANCE, focused on neurovascular diseases and stroke, incorporating approaches ranging from human blood to complex animal models, in partnership with a leading academic laboratory (PhIND, INSERM-UniCaen).
• SYNCROSOME, experts in cardiovascular pharmacology, with over 25 years of experience serving an international clientele.

These brands are now complemented by the creation of two new service brands, building on ETAP-LAB’s long-standing therapeutic areas:

• BRAINXPLORE, dedicated to diseases of the Central Nervous System (neurodegenerative diseases, behavioral pharmacology), offering a comprehensive and integrated range of preclinical services.
• SKINAXIS, specializing in dermatology, for the preclinical evaluation of the efficacy of drugs and medical devices, having contributed to the market launch of numerous innovative therapeutic products.

A Unified Visual Identity, Unveiled on the New Website

This evolution is accompanied by a redesign of the logos (see illustration at the end of this document*). ETAP-LAB and its service brands are adopting a common typographic identity, symbolizing maturity, rigor, and modernity. Each brand has its own graphic and color scheme, while maintaining an explicit link to the parent company through the “by ETAP-LAB” signature.

This new visual identity was unveiled with the launch of the new etap-lab.com website, which came online on April 29, 2026, offering an enhanced presentation of in vitro and in vivo pharmacology services, scientific expertise, and technology platforms, as well as a streamlined customer journey.

A Vision Driven by Scientific Rigor and Innovation

“This new identity marks a key milestone in our development. It reflects our ambition to strengthen our four areas of preclinical expertise by highlighting the scientific rigor and expertise that have earned our teams their reputation,” said Nicolas Violle, CEO of ETAP-LAB.

Over the next 3 to 5 years, ETAP-LAB aims to consolidate its position as a European leader while actively contributing to the development of innovative alternative methods (organs-on-a-chip, NAMs) to address the challenges of medicine today and tomorrow.

ETAP-LAB is evolving, restructuring its services, and reaffirming its values of Excellence, Transparency, Agility, and Customer Focus—all in support of a preclinical process that is more predictive, more ethical, and better tailored to the needs of pharmaceutical research.

About our partners/service providers:

We have chosen to work with local service providers based in Nancy, who are experts in their fields. For this extensive and strategic project, we relied on Thibaut Marquis (www.tmarquis.fr), a graphic and web designer based in Nancy, with whom we have been collaborating for many years on web and graphic design projects. Through his minimalist approach, attentiveness, and expertise, our service provider was able to precisely meet our needs and propose a new brand strategy accompanied by a coherent redesign of ETAP-LAB’s brand identity. Among the many resulting materials, Thibaut Marquis, in collaboration with a team of specialists, created the group’s website, which is designed to be dynamic and user-friendly. Discover this redesign at www.etap-lab.com. To maximize the visibility of the new website, we also turned to Grégory Ambroise of Supazena (www.supazena.com), an SEO consultant and search engine optimization expert.

L’article PR – ETAP-LAB Enhances the Clarity of Its Preclinical Offering with a New Brand Identity Unveiled on Its New Website est apparu en premier sur ETAP-LAB.

On this occasion, Nicolas Violle, CEO of ETAP‑LAB, will be attending to meet early‑stage biotech, pharma, and medtech companies and discuss the scientific and strategic challenges of preclinical drug development.

👉 Learn more about the event:
🔗 https://www.swissbiotech.org/event/swiss-biotech-day/

A key meeting point for the international biotech ecosystem

Bringing together several thousand participants from around the world, Swiss Biotech Day has become a major hub for innovation and partnering. The event fosters concrete discussions, scientific collaborations, and international partnerships among project leaders, CROs/CDMOs, industrial players, and investors, all focused on advancing innovative therapeutic programs toward the clinic.

For ETAP‑LAB, participation in Swiss Biotech Day is driven by a clear business objective: connect with project teams, understand their R&D challenges, and propose tailored preclinical support at critical stages of development.

Preclinical expertise dedicated to ambitious programs

ETAP‑LAB is an independent CRO with recognized expertise in in vitro and in vivo preclinical pharmacology, particularly in the fields of:

• Dermatology
• Cardiology
• Neurology, including CNS and stroke (ischemic and hemorrhagic)

Our mission is to support and accelerate drug candidate development by providing robust, translational models that generate reliable, decision‑enabling data throughout the preclinical phase.

A trusted partner built on rigor and proximity

With more than 35 years of experience, ETAP‑LAB is distinguished by:

• a high level of scientific rigor,
• full transparency throughout each project,
• strong responsiveness,
• and a close, collaborative client relationship, essential for building efficient and long‑term partnerships.

Meeting ETAP‑LAB at Swiss Biotech Day means engaging with a committed partner able to secure and streamline your preclinical development strategy.

📅 Schedule a meeting with ETAP‑LAB

ETAP‑LAB is registered on the official Swiss Biotech Day partnering platform.
👉 We invite you to book a one‑to‑one meeting with Nicolas Violle to discuss your projects and R&D challenges directly.

➡️ Schedule your meeting via the event’s partnering platform and meet us in Basel to move your preclinical programs forward together.

L’article Swiss Biotech Day 2026: accelerating preclinical development together est apparu en premier sur ETAP-LAB.

Three campaigns, three opportunities:January, February & March 2026 (with limited slots  per month)

Ready to start a new project with us? Discover our attractive prices!  

#1 PROTEINOPATHY PACK

Our Proteinopathy Pack is designed to assess compound efficacy against key neurotoxic protein oligomers — Aβ, Tau, or α-synuclein.  

• Primary rat neurons 
• Proprietary human oligomers — either Aβb, Tau or α-synuclein (stable, soluble & well-characterized) 
• 7 doses (typically 3-fold serial dilution) 
• Vehicle, negative & positive controls included 
• Endpoints: MTT-assay 
• Fast turnaround: results in 10 days  

#2 GLUTAMATE SYNAPTOTOXICITY PACK

Our Glutamate Synaptotoxicity Pack is designed to reveal the synapto-protection of your candidates with high precision and reproducibility, leveraging High Content Imaging and Analysis

• Primary rat neurons 
• 7 doses (typically 3-fold serial dilution) 
• Vehicle, negative & positive controls included 
• Endpoints: Immunofluorescence | synaptic proteins, neurite network, & nuclei, assessed through High-Content Imaging and Analysis. 
• Fast turnaround: results in 4 weeks 

Our scientific team is here to help you. Schedule a free consultation to discuss your study needs, explore the best assay options, and get expert guidance tailored to your CNS research goals. 

L’article Boost Your CNS Candidate Selection – Appealing Discount on Screening Campaigns. est apparu en premier sur ETAP-LAB.

We look forward to seeing you at this world’s largest neuroscience conference, organized by the Society for Neuroscience (SFN), with high-quality programming for scientists from around the world.

📅 When to meet our scientists

ETAP-Lab will unveil two scientific posters on original preclinical results:

Nicolas Violle, CEO and expert in Neuroscience, will present the latest results from our Neuroscience Lab with poster No. PSTR066.10 – “High-throughput brain-on-chip platform for accelerating neurodegenerative drug discovery”.
Session date and time: November 16, 2025, 8:00 AM – 12:00 PM.

Research in partnership with NETRI on the BIO-DIAMOND* program.

REQUEST THE POSTER

Annelise Letourneur, Preclinical Director at STROK@LLIANCE lab, will present the exclusive results of studies conducted for a client, including the successive preclinical stages at STROK@LLIANCE in the development of its stroke drug candidate, with poster No. PSTR443 – “A Translational Multi Model Platform for Preclinical Evaluation of Thrombolytics in Acute Ischemic Stroke”.
Session date and time: Wednesday, November 19, 2025, 1:00 PM – 5:00 PM.

REQUEST THE POSTER

📍 Where to find us

For the first time, we will welcome you at booth #534, with our expert teams ready to advise, as well as Sandra Robelet, our Business Developer.

You will also have the opportunity to meet our new American partner, GEN2X, based in San Diego. We have big surprises in store at our booth, so come and visit us.

🧠 Our models, designed to meet your challenges

We understand the challenges involved in your research to develop your drug candidates.

Do you want to optimize the development of your neurological drugs through translational preclinical studies? Do you need to know how to test the efficacy of your drug candidates? Do you need to reproduce the pathological characteristics of degenerative neurological disorders?

Our teams are committed to providing you with the best advice, quality services, and translational models to facilitate your transition to the next stages, all the way to clinical trials.

SCHEDULE AN APPOINTMENT – WELCOME TO OUR BOOTH #534

More to discover:
Have a look at our range of models and readouts in Neurovascular & Neurology fields.
Register for the congress: Sessions and Events
BIO-DIAMOND program advances here: https://netri.com/biodiamond/

Even more to discover when coming to visit us

We offer efficacy, drug interaction and non-regulatory safety studies in the fields of neurovascular and neurological diseases. Our neuroscience offering relies on a broad portfolio of in vitro to in vivo efficacy models for neurodegenerative diseases (proteinopathies, AD, PD and more), psychopharmacology (motor, mood and learning disorders), as well as ischemic and hemorrhagic strokes. We also offer novel in vitro Brain-on-Chip models.

BIO-DIAMOND program*: a collaborative project with NETRI aiming to accelerate the time-to-market of drug candidates in the discovery and preclinical phases for Alzheimer’s disease and other neurodegenerative diseases. Winner of the “Innovations in biotherapies and bioproduction” call for projects, financed by the French government as part of France 2030.

L’article SfN NEUROSCIENCE 2025 – Empower your drug candidates with our translational preclinical models est apparu en premier sur ETAP-LAB.

L’article Pitch at the TECNIPLAST Scientific Symposium France 2025 est apparu en premier sur ETAP-LAB.

We are proud to announce that ETAP-Lab, preclinical CRO expert in neuroscience, partnered with Revvity, leader in High Content Screening (HCS) solutions, to push the boundaries of discovery by combining their expertise and technology.

Revvity has just launched the staining kit for astrocyte differentiation – tested and approved by ETAP-LAB – specially designed for iPSC-derived neuronal models.

At ETAP-LAB, our teams contributed to this successful launch thanks to:

• our neuroscience expertise, delivering reliable and reproducible cellular models,
• the use of HCS technologies on our in vitro models of neurodegenerative diseases
• the careful selection of antibodies and the validation tests carried out on hiPSCs

Explore our platforms – Operetta CLS High Content Screening by Revvity: https://www.etap-lab.com/our-platforms/ 

Revvity’s product launch in details

The PhenoVue Astrocyte Differentiation Staining Kit offers a reliable solution for confirming the phenotype of astrocytes using a multiplex staining approach. PhenoVue™ reagents are suitable for high-content imaging applications. These brand-new preconfigured kits, containing dyes, reagents, and a detailed protocol, have been carefully tested and approved using ETAP-LAB’s expertise to accelerate workflows.
This is a reliable and easy-to-use solution for qualifying astrocyte differentiation and assessing activation states based on cellular morphology. Discover the kit in Revvity’s webiste.

L’article The collaboration with Revvity resulted in the launch of their staining kit, tested and approved by ETAP-LAB! est apparu en premier sur ETAP-LAB.

👇 Here below is a look back in video at the 𝙄𝙣𝙖𝙪𝙜𝙪𝙧𝙖𝙩𝙞𝙤𝙣 𝙤𝙛 𝙎𝙏𝙍𝙊𝙆@𝙇𝙇𝙄𝘼𝙉𝘾𝙀 𝙗𝙪𝙞𝙡𝙙𝙞𝙣𝙜 in Caen in September 2024, a major event in ETAP-Lab’s human and scientific adventure!
Since then, it has boosted our capacity for preclinical stroke research and opened up opportunities to work with more new clients.

For more details about this new building, our partners and our capacities in stroke research, you can read our Press Release here.

L’article 1st Anniversary of the STROK@LLIANCE building’s inauguration! est apparu en premier sur ETAP-LAB.

🔗 Learn more about the ESDR Meeting

Meet our team at Booth #2

Our team will be pleased to present our offer of preclinical dermatological models in skin inflammation, wound healing as well as skin grafting.

Schedule a meeting now with Jean-François Bisson, PhD, Director of Studies, and Jérôme Bernard, Chief Business Officer, by contacting us.

I want to schedule a meeting

Poster session – spotlight on our ischemic skin wound model

Don’t miss our scientific poster (#518), presented by Jean-François Bisson, highlighting the results of a client study on ischemic skin wounds, conducted in collaboration with École Polytechnique, Laboratoire de Physique des Plasmas and Plasana Médical.

This study contributed to the preclinical development of the Plasana One® technology, an innovative device now entering clinical trials, designed to efficiently treat chronic wounds such as venous leg ulcers and diabetic foot ulcers.

Poster title: “Pro-healing effects of Plasana One®, an argon-generated cold plasma on ischemic skin wounds”
Poster available for download after the conference.

REQUEST THE POSTER NOW

From gold standard models to tailored solutions for your specific dermatology projects

At ETAP-Lab, a French preclinical CRO for over 30 years, we offer in vivo preclinical research services in the dermatology field.

Leveraging our gold standard models and tailor-made solutions, we support your molecule development across areas such as psoriasis, atopic dermatitis, wound healing and skin grafting, using our platforms (microsurgery, stereotaxy, behavior, bioassays, (immuno)histology and more).

Explore our full range of dermatological models.

Event details:
📅 When: September 10–13, 2025
📌 Where: Flanders Meeting & Convention Center Antwerp – “A Room with a Zoo”
Address: Koningin Astridplein 20–26, 2018 Antwerp, Belgium
🎫 Register: https://esdrmeeting.org/registration/

We look forward to discussing your thoughts and exploring potential collaborations.

About Plasana Médical:

Plasana Médical was created by Yves Matton, from the startup studio Technofounders, and Professor Antoine Rousseau, Research Director at the Plasma Physics Laboratory (LPP) at École Polytechnique.

The company was founded in 2022, after more than 10 years of research on plasma medicine at LPP and following initial successful preclinical trials demonstrating the beneficial effects of cold plasma on wound healing.

This new type of treatment accelerates healing time and limits infections thanks to the antiseptic effect of cold plasma. Plasana Médical’s mission is to bring this technology to market to improve patients’ quality of life, facilitate the work of healthcare professionals, and reduce healthcare costs.

L’article ESDR Meeting 2025 – Rediscover Our Preclinical Dermatology Expertise est apparu en premier sur ETAP-LAB.

ETAP-Lab will be present at the AFSSI Connexions 2025 in Toulouse on July 1 and 2 to present the poster resulting from the research work of the laboratory dedicated to Neurology and Neurodegenerative Diseases.

Healthcare R&D and Innovation: French preclinical CROs at the heart of European leadership

AFSSI (the French Association of Service and Innovation Companies), in partnership with AD’OCC, the Occitanie region’s economic development agency, is organizing the 12ᵉ edition of AFSSI Connexions on July 1 and 2, 2025 in Toulouse. This annual event brings together key players in preclinical research and healthcare innovation for two days dedicated to exchanges and the creation of synergies.

🧠 We’ll be there to meet you, and Sandra Robelet will be presenting the poster “Advancing Alzheimer’s disease (AD’s) models for preclinical drug testing”*, which continues the work presented in 2024, demonstrating how we can screen the next generation of AD treatments thanks to in vitro models, combining neuron and glia, using Brain-on-Chip devices and targeting both amyloid and tau.

Join us for this 12ᵉ edition of AFSSI Connexions, moments of exchange and sharing. It’s an opportunity to discover our preclinical skills, know-how and innovations essential to Life Sciences players.

Contact us to receive the PDF poster or for a meeting!

Contact us

This year’s key themes:
The growth challenges facing the French preclinical CRO sector
The liability stakes relating to the use of animals for scientific purposes

Find out more about the program and register!

*About the poster:
A part of this project is co-financed by the Region Grand-Est and the European Union through the FEDER-FSE Lorraine and Massif des Vosges 2021-2027 operational program.
BIO-DIAMOND project, NETRI and ETAP-Lab industrial consortium, is funded by the French government as part of the France 2030 call for proposals “Innovations in biotherapies & bioproduction”.

L’article Neurology poster at the AFSSI Connexions 2025 est apparu en premier sur ETAP-LAB.

ETAP-Lab will be presenting a poster during the next edition of the SPIN 2025 Congress, organized every 3 years by the René Touraine Foundation, focused on Skin Inflammation & Psoriasis diseases.

Let’s talk inflammation at SPIN with our poster on our reference models using our unique translational approach focused on assessing rodent behavior and well-being. We share an overview of over 10 years of study results, showing just how reproducible and significant our findings are.

If you are interested in our latest insights on Psoriasis & Atopic Dermatitis, you can join our team!

Jean-François BISSON, PhD, Study Director of our preclinical dermatology laboratory, and Lianna RAZAFITRIMO, in vivo Preclinical Project manager, present the poster on “Behavioural assessment as a tool for evaluation of efficacy therapies associated with well-being recovery in preclinical models of skin diseases”.

About the congress:
At the International Conference of SPIN Skin Inflammation & Psoriasis International Network
In Paris – from July 2 to 4
Poster Walks – at Foyer Moebius – Thursday, July 3, 12:00–13:00

As a preclinical expert in skin diseases for over 20 years, ETAP-Lab is committed to remaining at the forefront of dermatological science. We look forward to discussing your thoughts and exploring potential collaborations.

ASK FOR A MEETING

Request our PDF poster when available!

L’article Preclinical Dermatology – Discover our Poster at SPIN 2025 Congress in Paris est apparu en premier sur ETAP-LAB.

Meet our expert during the poster session

L’article Neurodegenerative diseases & microfluidic platform – Poster session at the MPS World Summit in Brussels est apparu en premier sur ETAP-LAB.

We’re proud to share that in 2024, we achieved a 100% customer satisfaction rate, with an average score of 9.3 out of 10.

It’s important for us to establish a trustful and long-lasting relationship with our customers. That’s why we asked our customers to evaluate the quality of their collaboration with us throughout the 2024 studies. The results speak for themselves: 100% of respondents reported being fully satisfied with their experience working with ETAP-Lab and our laboratories.

Our clients value our expertise, the quality of our studies, and our flexibility. They particularly appreciate our dedicated teams, known for their attentiveness, responsiveness, and clear communication throughout every stage of the study.

We provide dedicated support and guide our clients every step of the way, advancing in vitro & in vivo preclinical studies – whether for new treatments, medical devices, pharmaceuticals or active compounds. Our flexible, human-scale organization allows us to provide tailored services across several fields: neurology, neurovascular research, cardiology, and dermatology.

Ready to start your next drug efficacy study? Get in touch today to discover how ETAP-Lab can help drive your success.

To go further about ISO9001:v2015 certification:

In 2024, ETAP-Lab has successfully renewed its ISO9001:v2015 certification. This achievement underlines its commitment to providing exemplary preclinical research services. Robust quality management system developed over 10 years ago, backed by ISO9001 certification, ensures quality, reliability and customer satisfaction.
The certificate was granted by OFC until October 1, 2027 for its Quality Management System for consulting, advising and study expertise in the field of in vitro and in vivo preclinical research.

L’article 100% of Customer Satisfaction in 2024 est apparu en premier sur ETAP-LAB.

Want to know more about our preclinical expertise and services?

Meeting request or Request our Portfolio of models

JNBB | National Biomedicines Manufacturing Day
June 5, 2025 | ORAL & BOOTH | Nancy, France.
Organized with MTInov, ENSAIA, BioValley France & France BioLead

About the event: https://www.france-biolead.fr/en/content/jnbb2024

MPS Microphysiology Systems World Summit
June 9 – 13, 2025 | POSTER | Brussels, Belgium.
Organized with EUROoCS
About the event: https://mpsworldsummit.org/

Bio Convention US
June 16 – 19, 2025 | BtoB PARTNERING & BOOTH #1935 | Boston, USA.
Organized with Eurobiomed & Biotechnology Innovation Organization
About the event: https://convention.bio.org/bio-2025

AFSSI Connexions
Juy 1 – 2, 2025 | POSTER & BtoB MEETING | Toulouse, France
Organized with AFSSI Sciences de la Vie
About the event: https://www.afssi-connexions.fr/

SPIN | Congress of the Skin Inflammation & Psoriasis International Network
July 2 – 4, 2025 | POSTER | Paris, France
Organized with Fondation René Touraine
About the event: https://spincongress.org/synoptic-program/

L’article Upcoming events to meet our experts across Europe & US est apparu en premier sur ETAP-LAB.

When: from May, 15th to 17th.
Where: on Campus Belval, at University of Luxembourg, in Luxembourg.
Poster session: POSTER #2 on May, 15th

🧑‍🔬 Meet our expert during the poster session
Dr Ahmad Allouche, Head of in vitro Biology, will be presenting the poster on “Neuroinflammation Models of Neurodegenerative Diseases”.
Let’s meet there to explore our in vitro & in vivo services dedicated to AD’s & PD’s translational neuroscience, especially focused on proteinopathies & other neuronal injuries.

🧠 At ETAP-Lab we support biotech & pharmaceutical companies to accelerate the development of transformative neurodegenerative therapies, aiming at a better future for all those affected by neurodegenerative diseases.

You can connect with us for a meeting or for more details on our models portfolio:

ASK FOR A MEETING

 🔬If you are not going to this event, don’t hesisate to request our PDF poster when available!

Focus on the 8th edition:
As one of the major international events on Neuroinflammation, this meeting will focus on the theme “Cerebral immune activation at the crossroads of healthy aging, senescence and neurodegeneration” encompassing basic, clinical, methodological and emerging perspectives and including internationally renowned scientists with expertise across a wide range of domains, as main speakers.
The conference offers new grounds for scientific exchange, joint strategies and collaborative actions within the Neuroinflammation community on an international level.
More about the scientific programme: https://neuroinflammation.uni.lu/programme/

L’article Neuroinflammation – Poster session at the Venusberg Meeting in Luxembourg est apparu en premier sur ETAP-LAB.

Come & discover the company during a presentation of ETAP-Lab’s activities in preclinical research for innovation in healthcare.

And meet our recruiters all afternoon for a jobdating!
Pascale ROZAN and Tyffanie PILLER will be on stand all day at the Animalerie Pédagogique – Agrocampus des 2 Vallées in Vendôme.

L’article LABDATING in Vendôme – Always on the lookout for future talent! est apparu en premier sur ETAP-LAB.

L’article See you at SKIN SUMMIT in France est apparu en premier sur ETAP-LAB.

L’article See you at the AAN 2025 Annual Meeting in San Diego est apparu en premier sur ETAP-LAB.

L’article Visit our booth & poster at AD/PD 2025 conference in April est apparu en premier sur ETAP-LAB.

• Novel targets beyond Aβ
• Deciphering disease complexity
• Enhancing α-synuclein detection
• Advancing blood-based biomarkers

L’article Let’s meet at AD’s & PD’s Drug Development Summit in Boston! est apparu en premier sur ETAP-LAB.

L’article Health Investigation on French TV: “Our Lives with Parkinson’s” est apparu en premier sur ETAP-LAB.

As a leading international conference in cerebrovascular disease and brain health, the AHA’s International Stroke Conference was the ideal platform to highlight our preclinical stroke research expertise.

ETAP-Lab, preclinical efficacy CRO, will be presenting its poster on original preclinical results about in vivo trials on Stroke disease.

📅Meet our expert during the poster session

Dr Annelise LETOURNEUR, Director of Operations at STROK@LLIANCE and Neuroscience Study Director, will present the poster “ Translational Relevance and Versatility of the Thromboembolic Stroke Model in Mice: Implications for Pharmacological and Safety Evaluations” (#4166454).

👩‍🔬Session details:.

Join her during her poster session on February 5, 2025 from 7:00 PM to 7:30 PM – Poster Board Number: WP364 – Hall G, Poster Hall (LA Convention Center)

🧠Our specific stroke models, reproducing translational challenges.

Would you like to support the development of your neurological drugs with translational preclinical models?

Thanks to our robust expertise in preclinical neurology, we can advise with relevant and translatable range of stroke models from in vitro to in vivo. Our key innovation is to offer models in optimal translational situations that combine stroke with metabolic diseases, diabetes or aging.

More to discover:

• Register now to the conference: https://professional.heart.org/en/meetings/international-stroke-conference/registration
• Have a look at our wide range of models in Neurology field and especially in stroke!
• You can connect with us and ask for the poster in PDF.
• Discover STROK@LLIANCE, our lab dedicated to stroke research in France

L’article Join us at the annual International Stroke Conference next February in Los Angeles! est apparu en premier sur ETAP-LAB.

When art and biology meet, it results in #FluorescenceFriday!

We regularly share our most beautiful images, and love to look curiously at the publications of other passionate scientists. Join us by following the hashtag #FluorescenceFriday on LinkedIn

if you’re eager to be amazed, to have glitter in your eyes while learning something new. 🌟🔬

Here are just a few of the images we’ve shared in 2024 focused on neurology field – original pictures all captured by ETAP-Lab© on our platform. And more to discover in 2025…

For instance you can observe the complex world of dopamine neurons used in Parkinson’s disease research, even a pro-inflammatory response in Alzheimer’s disease or an anti-inflammatory effect in astrocytes…

L’article Celebrating the Beauty of Biology! est apparu en premier sur ETAP-LAB.

This program – financed by the French Ministry of the Economy, Finance and Industrial and Digital Sovereignty – will support the growth of 12 innovative French companies in the healthcare sector. They will benefit from personalized support, including advice, training and networking opportunities.

During this eighteen-month program, we’ll be working on the challenges of a hyper-growth company, such as structuring strategy, business plan, commercial and international development, and ecological transition.

For Nicolas Violle, CEO of ETAP-Lab, “It’s an honor for ETAP-Lab to take part in this highly selective program of support for innovative healthcare companies. With the support of the BPI, we will be able to confront and refine our global growth strategy, and in particular the launch of innovations from our France 2030 programs. The result will be a change of dimension for ETAP-Lab, and an asset for the French pharmaceutical research sector.

To find out more about this program, read the Press Release: https://www.bpifrance.fr/catalogue-offres/accelerateur-industries-et-technologies-de-sante-3eme-promotion

L’article Integration into the Health Industries and Technologies Accelerator est apparu en premier sur ETAP-LAB.

A commitment to quality and customer satisfaction

Our robust quality management system, backed by our ISO9001 certification, ensures to our customers:

• compliance with rigorous quality standards: we follow established protocols and guidelines to ensure the accuracy and reliability of our services.
• Continuous improvement: We constantly focus on improving our processes and services, driven by a commitment to excellence.
• Customer-focused approach: Your satisfaction is essential to us. We work closely with you to understand your specific needs and provide tailor-made solutions.

When you choose ETAP-Lab, you benefit from our proven experience in providing high-quality preclinical research services. Our team of experienced scientists and technicians is dedicated to providing the highest level of expertise and support.

The certificate was granted by OFC from October 2, 2024 to October 1, 2027 for its Quality Management System for “consulting, advising and expertise of studies in the field of in vitro and in vivo preclinical research”.

Access to the certificate

L’article ETAP-Lab renews its ISO 9001 certification: Your assurance of quality, reliability and customer satisfaction est apparu en premier sur ETAP-LAB.

Our dedication to building lasting relationships goes beyond expertise. Our flexible and human-sized organization offers personalized support, ensuring clients feel empowered throughout the research process.

Ready to collaborate on your next drug efficacy study? Contact us today to explore how ETAP-Lab can contribute to your success!

More about the partnership with Kisolite: https://www.kisolite.com/partnerships

L’article IBD Research – ETAP-Labs and Kisolite Corp enter into partnership. est apparu en premier sur ETAP-LAB.

ETAP-Lab’s team is looking forward to attending this global event that explores “the forefront of stroke and cerebrovascular disease topics and present the most influential late breaking clinical trials”.

As a preclinical efficacy CRO, ETAP-Lab will unveil its poster on original preclinical results about in vivo assays on Stroke disease.

The results presented have been possible also thanks to STROKTURA* program.

📅Join our expert during the poster session

Annelise LETOURNEUR, Director of Operations at STROK@LLIANCE and Neuroscience Study Director, will present the poster

“Translational models of hemorrhagic transformation to evaluate the safety of new therapies in acute stroke: effects of age and hypertension in diabetic mice“.

Session details:

• Session Name: 0460 – SHORT COMMUNICATIONS 02: BASIC SCIENCE AND TRANSLATIONAL RESEARCH & DATA SCIENCES AND ARTIFICIAL INTELLIGENCE (ID 1584)
• Date : Wed, 23.10.2024
• Session Time: 14:00 – 15:30
• Room: Hall G
• Lecture Time: 14:56 – 15:00

🧠Our specific stroke models, reproducing translational challenges.

Would you like to support the development of your neurological drugs with preclinical studies? Do you need to test the efficacy of your molecules in translational models that mimic different commorbidity parameters?

Thanks to our robust expertise in preclinical neurology, we can advise with relevant and translatable range of stroke models from in vitro to in vivo. Our key innovation is to offer models in optimal translational situations that combine stroke with metabolic diseases, diabetes or aging.

More to discover:

• Have a look at our wide range of models in Neurology field and especially in stroke!

• You can connect with us at marketing@etap-lab.com and ask for the posters in PDF.

*About STROKTURA

STROKTURA, Stroke for the Future, aims to find innovative solutions in brain imaging applied to preclinical models of stroke, with the purpose of testing future therapies for ischemic strokes in humans. This project, led by our team of experts in collaboration with BB@C, with scientific and technical support from PhIND, ESR3P, and CYCERON, is financially supported by FEDER and the Normandy Region.

L’article Join us at the 16th World Stroke Congress in Abu Dhabi this October! est apparu en premier sur ETAP-LAB.

That meeting is the World’s Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with an exciting programming for the scientists coming from around the world!

ETAP-Lab will unveil two posters on original preclinical results about in vitro and in vivo assays on Alzheimer’s disease.

📅Let’s meet our scientists during the poster sessions

• Nicolas Violle, CEO and expert in neuroscience, will present the poster #PSTR013.14 – Towards new relevant neuroinflammation models using oligomers involved in Alzheimer’s disease for target validation and drug testing. Poster presentation on Day 1 Sat., Oct. 5, 2024 from 2 p.m. to 3 p.m.

• Julie Colin, Preclinical Project Manager in Neuroscience, will present collaborative results with our partner NETRI, also exhibiting in the congress – with the poster #PSTR387.08 – Brain-on-chip technology and high-content analysis system to improve and accelerate preclinical Alzheimer’s disease drug research. Poster presentation on  last Day, Wed., Oct. 9, 2024 from 11 a.m. to noon

🧠Our Neurological models, tailored to your challenges.

Would you like to empower your neurological drug development through preclinical studies ? You need to know how to test the efficacy of your molecules and your proof of concept?  You need to mimic the pathological features of NDD’s?

At ETAP-Lab we can advise with our relevant and translatable in vitro and in vivo models. We have developed a wide range of neurodegenerative diseases models (Alzheimer and Parkinson), as well as stroke models​ and in vivo models of young & aged rodents​ in psychopharmacology!

We also propose novel in vitro Brain-on-chip models that are developed in BIO-DIAMOND Project, a collaborative project with NETRI aiming at accelerating the time-to-market of drug candidates in the “discovery” and “pre-clinical” phases in the fields of Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

France 2030 supports “Innovations in biotherapies and bioproduction” by selecting the NETRI and ETAP-Lab industrial consortium. Winners of the “Innovations in biotherapies and bioproduction” call for projects, financed by the government as part of France 2030, NETRI and ETAP-Lab have launched their BIO-DIAMOND project in 2023.

More information about the project advances here: https://netri.com/biodiamond/

More to discover:

• Have a look at our wide range of models in Neurology field!

• You can connect with us at marketing@etap-lab.com and ask for the posters in PDF.
• Discover the congress: https://www.sfn.org/meetings/neuroscience-2024

L’article Discover our latest NDD’s results at the NEUROSCIENCE 2024 in Chicago est apparu en premier sur ETAP-LAB.

CAEN – ETAP-Lab, an independent French contract research organization (CRO), will inaugurate its new research laboratory, STROK@LLIANCE, on September 17, 2024, at 14:30. The event will take place on the Jules Horowitz campus in Caen, with the participation of its partners and representatives from the University of Caen-Normandy, Caen la Mer, and the Normandy Region.

A multi-voice ceremony

For this inauguration ceremony at STROK@LLIANCE, Nicolas Violle, CEO of ETAP-Lab, is pleased to bring together employees from ETAP-Lab’s three sites, as well as its partners – notably ESR3P, CYCERON, and BB@C. ETAP-Lab also has the privilege of welcoming local stakeholders, with speeches from the President of the University of Caen-Normandy, representatives of the urban community Caen la Mer, and the Normandy Region. Professor Denis Vivien (PU-PH), a renowned scientist and Director of the BB@C institute and the PhIND Laboratory, will also speak, along with Hugues Contamin, President of AFSSI (French Association of Service and Innovation Companies for Life Sciences), representing the French preclinical CRO sector to which ETAP-Lab belongs.

A sustainable local presence, promoting employment, research, and innovation

Established in Caen for 7 years under the brand name STROK@LLIANCE, and leveraging the research of its academic partner PhIND, ETAP-Lab has experienced significant growth – directly creating 13 jobs on site. To support its growth, it decided to increase its capacity by acquiring a building on the Jules Horowitz campus. After a year of renovation and expansion work, the teams moved into this new building, fully operational since July 2024. ETAP-Lab invested 2.4 million euros in this project, mostly funded by its own resources, with financial support from Caen la Mer through a zero-interest loan of 250,000 euros and a 50,000-euro grant from the Normandy Region.

Stroke, a global health challenge, supported by preclinical companies

Each year, 15 million people worldwide suffer a stroke, with one-third of patients dying within the following weeks and another third suffering permanent disability. In France, 130,000 people are affected by stroke each year. STROK@LLIANCE offers preclinical stroke models and is involved in the early stages of drug candidate development for the pharmaceutical industry. By providing cutting-edge preclinical research services, it rigorously and independently evaluates the efficacy and safety of its clients’ molecules – a prerequisite before any clinical trial in humans.

STROK@LLIANCE: Enhanced capabilities to meet the accelerating stroke research needs of the pharmaceutical industry

Currently, there is only one emergency treatment for strokes, and epidemiological studies predict a 70-80% increase in their incidence by 2050. In this context, the pharmaceutical industry is intensifying its research to develop new therapeutic solutions. The new 700 m² facilities of STROK@LLIANCE meet clients’ needs by tripling neurology research capacities while remaining at the heart of biomedical research and innovation at the CYCERON center. With its extensive experience in preclinical pharmacology and the integration of innovations from the PhIND laboratory, ETAP-Lab offers its unique expertise to its clients. Since 2017, its research has contributed to the development of numerous molecules, representing new hopes for stroke treatment.

About ETAP-Lab

ETAP-Lab is an independent contract research organization (CRO) established in 1991 in Vandoeuvre-Lès-Nancy (Grand-Est). It offers efficacy and safety evaluation services for drug candidates to pharmaceutical and biotechnology industries – an essential step before any clinical trial of innovative therapies in humans. With over 30 years of scientific expertise, it supports clients with preclinical studies in various therapeutic areas, including Dermatology, Neurology, and Cardiology, through the integration of SYNCROSOME in October 2023. With a team of 45 employees across three sites in France, ETAP-Lab supports over 300 clients worldwide. In 2023, its turnover reached 3.4 million euros (+74%), with 80% from exports. It strengthens its market position through external growth and strategic research projects.

For more information:

ESR3P: Experimental platform dedicated to stroke at the University of Caen-Normandy, affiliated with INSERM UMR-S 1237, PhIND, directed by Professor Denis VIVIEN.

STROK@LLIANCE: Born from the virtuous association between ETAP-Lab and ESR3P, offering the best of academic and CRO expertise in the field of stroke within a state-of-the-art scientific and technological complex.

L’article PRESS RELEASE – Research against stroke: ETAP-Lab unveils its new private research laboratory est apparu en premier sur ETAP-LAB.

We are delighted to participate for the first time to Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry.

🎯 Explore our wide range of services, from gold-standard to tailored models designed to tackle your challenges
You look forward accelerating & derisking the development of your drugs and/or medical devices in Dermatology, Neurology, or Cardiology thanks to preclinical efficacy studies ?
At ETAP-Lab – French preclinical CRO for over 30 years – we support your preclinical development thanks to relevant & translatable in vivo and in vitro models implemented by our research team !
You can have a look at our wide range of models in our website !

📆 Let’s discuss your challenging issues
Our Business Developer is ready to advise on your specific needs. Just ask for a meeting with Jérôme Bernard during NLSDays One-on-One Partnering:
– Directly through the NLSD online portal 
– You can’t join us ? You can also request a virtual appointment with our expert to tell us about your needs

Looking forward to connect with your company !

L’article Meet ETAP-Lab at NLSDays 2024 for Partnering Opportunities est apparu en premier sur ETAP-LAB.

🔬To support our research activity in the fields of dermatology and neurology, our new premises will incorporate larger laboratories, more office space for the support departments and all the facilities to ensure the well-being of our employees, all in a building with a footprint of 1600m², including 700m² of laboratories.
With this new lab, our overall research capacity will be multiplied by three, with the possibility of further extension on our 400m² grounds.

ETAP-lab is strengthening its roots in Nancy, at the heart of an ecosystem that fosters medical research and innovation: close to the CHRU of Nancy and the IHU INFINY, and to the Faculty of Medicine at the University of Lorraine.

We would like to thank all contributors to this ambitious project:
– Our architect LCR Les Constructeurs Réunis 
– Our many local supporters Grand Nancy Innovation, Métropole du Grand Nancy, Lorr Up – Agence de développement économique Nancy Sud Lorraine …

🤩 Now we can’t wait for the work to start, hopefully in 2024…

L’article ETAP-Lab’s future facilities unveiled est apparu en premier sur ETAP-LAB.

We look forward to participating in the 3rd HF Drug Discovery & Development Summit, which returns to tackle the major challenges facing preclinical heart failure drug development by bringing together more than 50 biopharmas delve into targeting, stratifying and treating cardiomyopathies with greater precision.

A fine programme of scientific conferences and poster sessions in prospect! SYNCROSOME, as the cardiology branch of ETAP-Lab, will be presenting a poster on original cardiovascular preclinical results.

📆 Let’s meet at our scientific poster session

Our team will present our original results supporting development for HF & cardiomyopathies.

Come and discover our poster and see you on 31 July 2024 at 4.25 am on day 1.

🫀 Our cardiovascular models, tailored to your HF challenges.

Would you like to accelerate the development of your cardiology drugs and/or medical devices through preclinical studies ?

At ETAP-Lab – a French preclinical CRO for over 30 years – we can accelerate, derisk and support pharmaceutical companies’ preclinical development with relevant and translatable in vitro and in vivo models !
We offer a wide range of services dedicated to modelling cardiovascular diseases such as HFrEF, HFpEF, acute myocardial ischaemia and arterial/pulmonary hypertension…

More to discover:

• Have a look at our wide range of models in Cardiology !
• You can connect with us at marketing@etap-lab.com and ask for the poster in PDF.
• Discover the HF Summit

L’article Syncrosome as Event Partner of 3rd HF Drug Discovery & Development Summit in Boston est apparu en premier sur ETAP-LAB.

Jérôme Bernard, CBO, explains: “As a CRO, we have to be at the forefront of innovation to help our clients to derisk their molecules and programs“.

▶️ Discover the integral interview on IBTV channel.

L’article ETAP-Lab interview on IBTV est apparu en premier sur ETAP-LAB.

FENS Forum 2024, taking place in Vienna this year, is organized by the Federation of European Neuroscience Societies (FENS), the Austrian Neuroscience Association (ANA) and the Hungarian Neuroscience Society. The FENS Forum is Europe’s largest neuroscience congress, covering all areas of neuroscience from basic to translational research. It will feature an exciting programme of plenary and special lectures, scientific symposia, technical workshops, special interest events, career development and networking opportunities and so much more!

🎯 Our broad offering, tailored to your challenges

You look forward accelerating the development of your drugs and/or medical devices in Neurology thanks to preclinical studies ?

At ETAP-Lab – French preclinical CRO for over 30 years – we can accelerate, derisk and support your preclinical development thanks to relevant & translatable in vitro and in vivo models !

We developped a wide offer of neurodegenerative diseases models (Alzheimer and Parkinson) from in vitro to in vivo, as well as stroke models​ and in vivo models of young & aged rodents​ in psychopharmacology.

📆 Let’s meet in our booth 1004

Our team would be happy to meet you during FENS Forum and present our portfolio of neurological models. Let’s arrange a meeting Booth 1004 by contacting us at marketing@etap-lab.com and see you in Vienna !

🌿 A “sustainably-designed” event

ETAP-Lab is proud to participate to a sustainably-designed event designed by FENS Federation and carried out  according to the Guideline of the Austrian Ecolabel for Green Meetings and Green Events. In this context, they aim to support sustainable consumption and production, trying to save resources, avoid waste, and act in an environmentally conscious way in all fields. All shell schemes provided by Standout – like ETAP-Lab’s – are reusable (aluminium system), with energy-saving lighting systems (LED lamps), carpets are reusable and recyclable.

More to discover:

• Have a look at our wide range of models !
• Check out some concrete sustainable actions implemented by FENS
• Discover FENS Forum 2024 in video: FENS Forum 2024: Welcome to Vienna!

L’article Meet ETAP-Lab at the FENS Forum 2024 – Booth 1004 est apparu en premier sur ETAP-LAB.

➡ETAP-Lab, represented by its CEO Nicolas Violle, will be taking part in the round table “France 2030: how to support excellence in the healthcare sector in the territories?“

This round table will be featuring Charles-Edouard Escurat from the Agence de l’Innovation en santé, Jean-Luc Dimarcq from the IHU Strasbourg, and moderated by Jean Sibilia.

👉 You can find the full programme with other round tables and pitches from the stakeholdes shaping tomorrow’s healthcare and register here: https://www.biovalley-france.com/fr/agenda/nextmed-day-rapprochons-le-futur-de-la-sante/

🤝 An event organised by BioValley France, Nextmed Strasbourg, SATT Conectus, the University Hospitals of Strasbourg, with the support of Quest For Health and other members of the local innovation ecosystem.

L’article Nextmed Day – ETAP-Lab taking part in a round table est apparu en premier sur ETAP-LAB.

🧠Ahmad Allouche, one of our in vitro expert, explains:
“About the synaptic degeneration mechanism, it occurs early in neurodegenerative diseases and correlates with cognitive decline. Increased levels of synaptic proteins have been detected in the CSF in the early stages of Alzheimer’s diseases (AD) presumably due to release from degenerating synapses.
Postsynaptic density protein 95 (PSD-95, also known as SAP-90 or DLG4) is a scaffolding protein participating in the organization and regulation of synapses. It binds to NMDA and AMPA receptors, potassium channels, and associated signalling proteins resulting in their clustering during the formation and maintenance of dendritic spines. The dysregulation of PSD-95 expression has been associated with neurodegenerative disorders.

Reduced expression of PSD-95 has been observed in brain tissue from AD subjects and in mouse models of AD, making it an attractive target for developing strategies able to monitor PSD-95 accurately for therapeutics and diagnostics.“

Get in touch to develop your own study with our in vitro or in vivo models !

Image was acquired with Operetta® CLS™ High-Content Imaging System / REVVITY. Original picture © ETAP-Lab 2024.

L’article First #fluorescencefriday – the word of our expert est apparu en premier sur ETAP-LAB.

This annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering, bringing together thousands of global biotechnology and biopharmaceutical leaders.

🎯 Our broad offering, tailored to your challenges

You look forward accelerating the development of your drugs and/or medical devices in Dermatology, Neurology, Gastroenterology or Cardiology thanks to preclinical studies ?

At ETAP-Lab – French preclinical CRO for over 30 years – we can accelerate, derisk and support your preclinical development thanks to relevant & translatable in vivo and in vitro models !

📆 Let’s plan a meeting 

To determine how we could fit your specific needs, our Business Developers would be happy to meet you during BIO’s One-on-One Partnering™. Just ask for a meeting with Jérôme Bernard and/or Sandra Robelet:

• Directly through the online portal
• Can’t wait for it ? Or not enough time to meet there ? No worry, just contact us at marketing@etap-lab.com and let’s plan a call whenever you prefer.

🙏A supported French delegation

Thanks to the HealthCare innovation France 2030 plan, we are proud to participate to BIO International Convention in the French delegation made up with companies at the forefront of innovation. We send a warm thanks also to our French partners in this Business adventure: CCI International Grand Est, Business France Healthcare and Eurobiomed.

Looking forward to sustainably connect with counterparts in the U.S. and worldwide !

More to discover:

• Have a look at our wide range of models !

• Go to 2024 BIO International Convention
• Read our press release dated on 31th June, 2024

L’article ETAP-Lab to attend the 2024 BIO International Convention for Partnering Opportunities est apparu en premier sur ETAP-LAB.

📢 Today we’re delighted to announce that the building is up and running, with the laboratory section now ready for occupancy.

This is an important event for Strok@lliance, our site of excellence dedicated to stroke at the very best heart of a research center with the support of ESR3P, CYCERON and Institut BB@C.

👉 Follow with us the completion of the installation over the coming weeks…

L’article New building ready for STROK@lliance est apparu en premier sur ETAP-LAB.

In the Parkinson’s disease field, the notion of the origins of the pathology is still debated. Some studies contend that neuronal dysfunction and injury cannot occur without the demonstrable presence of inclusions, while other studies report the potential harm that alpha-synuclein oligomers can have.

This is reminiscent of another neurodegenerative pathology: Alzheimer’s disease. For decades, it was thought that amyloid beta deposited into plaques was the most harmful to neurons. However, more recent evidence points to diffusible, soluble small amyloid beta moieties as being the major neurotoxic form.

Many observations indicate that alpha-synuclein inclusion formation is not the major driver in the early phases of PD-like neurodegeneration, but that diffusible, oligomeric alpha-synuclein species, which drive synaptic degeneration, trigger neuroinflammation and ultimately induces loss of dopaminergic neurons. This could have important implications for the design of therapeutic interventions during the early stages of the disease.

🧠Always guided by our commitment to improving patients’ quality of life, at ETAP-Lab we develop state-of-the-art in vitro models being more translational to meet the needs of ou customers – pharmaceutical companies – and patients suffering from pathologies…

For example, our expert teams work on subsidized research project such as BIO-DIAMOND that help accelerate the modeling of diseases like Parkinson’s, and make possible the lab testing of tomorrow’s drugs.

Find out more information on all our services in neurodegenerative diseases at the following link: https://www.etap-lab.com/neurodegenerative-diseases/

BIO-DIAMOND project has emerged as a winner of the “Innovations in biotherapies and bioproduction” call for projects funded by the French government as part of France 2030.

L’article World Parkinson’s Day 2024 – Towards improved screening tools for Parkinson’s disease est apparu en premier sur ETAP-LAB.

🔬 Meet our expert, Dr. Ahmad ALLOUCHE, and learn more about this project.

💡 We are proud to present our innovative #BrainOnChip model designed to develop and explore drug efficacy in #Alzheimer’s disease.

Our model incorporates:
> Compartmentalized co-culture, showcased in the poster, featuring glutamatergic and GABAergic neurons derived from human induced pluripotent stem cells (hiPSCs).
> Fluidic isolation using NETRI’s DuaLink device and DuaLinkMEA device (MicroElectrodeArray).
> Integration of ETAP-Lab’s toxic oligomeric forms of human amyloid beta 1-42 (AβO).

Request a poster reprint : contact@etap-lab.com

This project is proudly funded by the French Government with “France 2023” under the call for proposals “Innovations in biotherapies & bioproduction”.

L’article Poster AD/PD International Conference | Brain-On-Chip Project est apparu en premier sur ETAP-LAB.

Over the years since it was founded, ETAP-Lab’s expertise in neurology and dermatology has been confirmed. With the arrival of SYNCROSOME, a renowned player in cardiovascular preclinical research, ETAP-Lab is now diversifying its offering while retaining its high-end service profile, at once both agile and specialised around strong core areas of expertise.

This strategic acquisition brings together the complementary skills, cutting-edge technologies and partner networks of two well-respected market players. It enables ETAP-Lab to provide customers and partners alike with innovative solutions that will ensure faster, more robust development of their therapeutic innovations.

To find out more, please read the official press release:  English  /   French

Keep an eye on our feed to make sure you don’t miss out on any news!

Follow us on

L’article ETAP-Lab announces the acquisition of SYNCROSOME est apparu en premier sur ETAP-LAB.

🚀 This acquisition marks a new stage in the company’s development.

Since its inception in 2000, SYNCROSOME has established itself as a key player in French preclinical research. By joining the ETAP-Lab group, SYNCROSOME is now bringing its expertise and innovative models to the in vivo evaluation of therapeutic strategy efficacy in cardiorespiratory medicine. SYNCROSOME’s expertise will also bolster ETAP-Lab’s historical activity in the field of neurology.

Given the synergies in terms of skills, technologies and scientific networks, this coming-together of the two laboratories will also strengthen the overall capabilities of the ETAP-Lab group. Moreover, SYNCROSOME will be able to draw on the scientific, technical, commercial and legal support of the ETAP-Lab group to accelerate development in its core areas of excellence, in line with the group’s overall strategy.

Nicolas Violle, now CEO of both SYNCROSOME and ETAP-Lab, said: “I am especially pleased to be working with Sandra Robelet and her team of scientists, whose expertise has consistently impressed me during the year we spent preparing this acquisition. I am also very confident that SYNCROSOME will be successfully integrated into the vision and growth strategy of the ETAP-Lab Group.”

To find out more, please read our official press release.

French

English

Keep an eye on our feed to hear all about this new adventure!

L’article SYNCROSOME is proud to announce that it has joined the ETAP-Lab group est apparu en premier sur ETAP-LAB.

Contact us

L’article Intracerebral administration in rat and mouse est apparu en premier sur ETAP-LAB.

This article focuses on the impact of surgical decompressive craniotomy in malignant ischaemic stroke, following endovascular thrombectomy, whether or not this is coupled with pharmacological thrombolysis (Actilyse, rt-PA).

By combining two different surgical techniques (the mouse model of ischemia-reperfusion and decompressive craniotomy) with the two therapeutic approaches used in the treatment of cerebral ischemia in humans (thrombectomy and thrombolysis), the authors have shown that combined with early reperfusion, decompressive craniotomy increases the risk of hemorrhagic transformation.

This preclinical data raises questions, and should lead to clinical investigations aimed at improving patient management.

For more detail: link to the article (open access)

We’d like to take this opportunity to congratulate all the authors on their work.

L’article New paper in STROKE est apparu en premier sur ETAP-LAB.

Download all informations (pdf)

Financial Disclosure

Artur Plonowski, Benjamin Pratt, Magdalena Krupa, Piotr Lipiński, Christopher Larson, and Mark Herbert are employees and/or shareholders of Vasa Therapeutics.

Role of MMP2, 9 and 13 in Heart Failure

• Elevated plasma MMP2 and 9 in hypertensive diastolic HF patients.
• Upregulated expression and activity in HFpEF comorbidities.
• Increased expression of MMP2, 9, and 13 in heart biopsies from patients with Dilated and Ischemic Cardiomyopathy.
• MMP2 and 9 Tg mice develop fibrotic myocardium.
• MMP2 and 9 KO and prototype pharmacological inhibitors protect from structural changes and functional deficit in animal HF models.
• Intracellular MMP2 and 9 mediate detrimental effects of ischemia, neurohumoral stimulation, hyperglycemia on cardiac contractility, Ca2+ cycling, and bioenergetics.

Plasma MMP2 and MMP9 could serve as biomarkers for precision medicine approach in HFPEF subpopulations.

Aim

Preclinical characterization of VS-041, a novel, orally bioavailable, and selective inhibitor of cardiac-relevant MMP2, 9, and 13, as a potential Clinical Development Candidate for treatment of HFpEF.

Methods

Small-molecule inhibitor of MMP2, 9, and 13 was synthesized by Vasa Therapeutics. Proprietary scaffold was designed and optimized using computer-aided platform (Schrödinger, MA).

In vitro methods
• IC50s against MMP2, 9, 13, MMP1, and TACE were determined using colorimetric assay (MMP2, 9, 13, and 1) or fluorimetric assay (TACE) (Enzo Life Sciences AG, Lausen, Switzerland).
• Sarcomere length transients were measured in adult primary mouse cardiomyocytes using Calcium and Contractility System (IonOptix LLC, Westwood, MA) with digital sarcomere geometry measurement. Cardiomyocytes were paced at 1 and 4 Hz (MyoPacer) in the presence of 1 uM of VS-041 or matched DMSO concentration (0.01%).
• ADME properties were determined using standard assays at Quintara Discovery (Hayward, CA). Protease selectivity was assessed at Reaction Biology Corp., Malvern, PA. In Vitro Safety Pharmacology profiling was determined at Eurofins Cerep (Celle l’Evescault, France).

In vivo methods
In vivo fractional MMP ooccupancy of VS-041 was determined based on unbound fraction (Fu) plasma exposure in Sprague Dawley rats after oral administration at 50 mg/kg. Compound concentration measured in plasma by fit for purpose LC-MS/MS. Rapid equilibrium of ligand-receptor binding was assumed.

Therapeutic efficacy study in HFpEF and hypertension Dahl-Salt Senisitive rat model
Study was performed by an independent Contract Research Organization (Syncrosome, Marseille, France).

Animals
Three-four-week old (on arrival) Dahl/SS male rats (SS/JrHsdMcwiCrl, Charles River, US), were used for this study. After one week of acclimation, HFpEF groups (n=11-12/group) received an 8% NaCl enriched diet (D05011703, Research Diets). Control group was fed the control diet containing 0.26% NaCl (D10001, Research Diets). Animals included in these experiments were naive to previous administration of any drug.

Echocardiographic analysis
The analysis of 2D-echocardiographic images was performed using the software included in the digital ultrasound system equipped with a 10 MHz phased-array transducer (Vivid 7, GE Medical Systems). All measurements were quantified blindly by a single trained operator and averaged over three consecutive cardiac cycles. Left ventricular (LV) dimensions and wall thicknesses were measured at the level of papillary muscles in M-mode to derive LV ejection fraction (EF). From Doppler spectra of mitral inflow, the isovolumic relaxation time (IVRT) and the peak velocity of early (E) and late (a) filling waves to calculate E/a ratio were measured.

Blood pressure measurement
Rats were deeply anesthetized with isoflurane (induction 4%, maintenance 2-2.5%) associated with buprenorphine (0.03mg/kg, SC) administrated 30 min before induction. Systolic blood pressure (SBP) recordings were performed using a catheter introduced into the carotid artery. Rats were prepared using standard surgical conditions and then intubated and ventilated. The carotid artery was catheterized and SBP recording were performed. A pressure transducer (BLPR (World Precision Instruments, UK) or equivalent) was connected to an amplifier (TBM4M (World Precision Instruments, UK) and a data acquisition unit (Powerlab 16S World Precision Instruments, Australia).

Histological evaluation
Each heart was sectioned at three anatomical transverse planes (Basal (cranial), mid, and caudal or apical ventricular regions) and stained with Sirius red (SR). Sections were digitized using a Nanozoomer (Hamamatsu) and were downloaded and visualized using NDP viewer. Each section was evaluated and individually scored.

Statistical analysis
ANOVA & Tukey Multiple Comp Test: *P<0.05, **P<0.01, ***P <0.001 vs HS. Two-tailed t-test: #P<0.05 vs LS.

The experimental procedures were carried out in accordance with European guidelines for the care and use of laboratory animals (Council Directive 2010/63/UE). The protocol was approved by an Animal Ethical Committee (French National Committee N°71) and by the Higher Education and Research Ministry (APAFIS#32833- 202108191651675 v3).

Results

Summary and Conclusion

• VS-041 is a potent, orally bioavailable and selective inhibitor of cardiac-relevant MMP2, MMP9 and MMP13.
• VS-041 reduces sarcomere contractility deficit due to fast pacing.
• VS-041 demonstrated a robust efficacy in Dahl Salt Sensitive rat model of hypertension and HFpEF (~40% improvement in diastolic function and dose-proportional decrease in LV fibrosis).
• VS-041 had no effect on blood pressure or ejection fraction suggestng a direct effect on diastolic function. No adverse effects were observed after 5 weeks of daily administration.
• Preclinical pharmacology and safety profile of VS-041 support its nomination as a Clinical Candidate and initiation of IND-enabling studies. Phase 1 clinical trial is anticipated in the 2nd half of 2023.
• VS-041 has potential to be first-in-class precision medicine treatment for HFpEF patients with elevated levels of cardiac- relevant MMPs.

Acknowledgements

Project co-funded by European Regional Development Fund and Polish National Centre for Research and Development:
Preclinical development and phase I clinical trial of innovative drug candidate for heart failure with preserved ejection fraction (HFpEF)
(POIR.01.01.01-00-1210/19-01).

1 Presenting and corresponding author: aplonowski@vasatherapeutics.com

L’article New cardiovascular model available at SYNCROSOME est apparu en premier sur ETAP-LAB.

Download the poster to learn more about his work !

A relevant model of thromboembolic stroke in diabetic mice for the preclinical evaluation of hemorrhagic transformation risk related to new therapeutic agents

L’article SfN 2022 – Poster est apparu en premier sur ETAP-LAB.

Florent Lebrun will share with you our last results concerning
“A relevant model of thromboembolic stroke in diabetic mice for the preclinical evaluation of hemorrhagic transformation risk related to new therapeutic agents” (Poster 287.19 – Abstract 5578 – Novermber 14th – Morning poster session).

We’d be delighted to meet you!

L’article Society for Neuroscience annual congress in San Diego (USA) – 12th to 16th november. est apparu en premier sur ETAP-LAB.

Nose-to-brain transport can either be mediated via the olfactory or the trigeminal pathway. Drugs passing along the olfactory pathway target the olfactory bulb, whereas drugs transported via the trigeminal pathway are delivered predominantly to the brain stem.

• Blood-brain barrier and the blood-cerebrospinal fluid barrier are major obstacles in CNS drug delivery, since they block most molecules from entering the brain.
• Nose-to-brain delivery is a minimally invasive drug administration pathway, which bypasses the blood-brain barrier as the drug is directed from the nasal cavity to the brain.

L’article NEWS for CNS Department est apparu en premier sur ETAP-LAB.

SYNCROSOME has acquired a new Echocardiograph

Vivid™ S60 , GE Healthcare

Logiciel version  : R3

Probes : 12S-D and linear probe L8-18i-D

Vivid™ S60 is used to measure cardiac morphological and functional parameters on anesthetized rats.

Cardiovascular models :

• Myocardial ischemia
• Heart failure
• Heart aging
• Pulmonary arterial hypertension

L’article NEWS for cardiovascular Department est apparu en premier sur ETAP-LAB.

>> Article

This article reports on the effectiveness of a new therapy for the treatment of bladder cancer. By means of longitudinal follow-up over a period of up to 30 days, and supported by histology and immunohistochemistry results, the findings highlight the effectiveness of the combination of photodynamic therapy and a checkpoint inhibitor.

>> For more details: Photocure Press Release

We’d like to take this opportunity to congratulate all the authors for their work.

Contact Us

L’article New research article est apparu en premier sur ETAP-LAB.

We are very pleased to be sharing this poster.

Download the poster

If you have any questions about our results, we’d be delighted to discuss them with you.

Contact Us  

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the “FEDER-FSE Lorraine et Massif des Vosges 2014-2020” operational programme.

L’article The ETAP-Lab poster presented at AD/PD 2022 is available online est apparu en premier sur ETAP-LAB.

Conducted in collaboration with Dr. @Manuel Buttini from Luxembourg (National Center of Pathology), this work shows that, in the early induction stages of the Parkinson’s disease process, diffusible alpha-synuclein oligomers spreeding is responsible for neurodegeneration and neuroinflammation. This induces microglia activation, prior to the formation of inclusions (#ParkinsonsDisease). These results are of considerable interest in terms of the development and evaluation of future therapies (#DrugDiscovery).

The significance of the scientific contribution made by this work was recently highlighted by Dr @Heather Wood (Chief Editor) in Nature Review Neurology.

For further information on alpha-synuclein oligomers, please see our dedicated neurodegenerative diseases page .

 Link to article   Link to editorial

Contact us

L’article Neurology: Alpha-synuclein oligomers involved in Parkinson’s disease pathogenesis! New publication in the journal GLIA, highlighted by NATURE REVIEW Neurology est apparu en premier sur ETAP-LAB.

24 Nov – Inauguration of the French Tech Central office in Caen – Annelise Letourneur (Assistant Director at STROK@LLIANCE ) will take part in a round table discussion at the Dôme in Caen from 3pm to 4:30pm.
We’d like to thank French Tech Caen Normandy for its support during ETAP-Lab’s development in Normandy.

L’article New -French Tech Central opens an office in Caen, Normandy est apparu en premier sur ETAP-LAB.

Nicolas Violle will be delighted to meet you and tell you about what we do at ETAP-Lab. A rare opportunity to connect with key players in the Lorraine region.

Thanks to BioValley France for making it happen!

Les biotechs du coin : un afterwork dédié au foyer lorrain

L’article Save the date – we’d love to meet you! est apparu en premier sur ETAP-LAB.

L’article Renewal of ETAP-Lab’s ISO 9001 certification (v2015)! est apparu en premier sur ETAP-LAB.

L’article Meet us at BIOEurope 2021! est apparu en premier sur ETAP-LAB.

L’article Meet us at BioEurope 2021! est apparu en premier sur ETAP-LAB.

With 35 preclinical studies under our belt, we’re proud to say we’ve already contributed to the progress of numerous R&D projects.

Our team in Caen is led by Dr Nicolas Violle and Dr Annelise Letourneur, and currently employs 5 people. With ever-increasing demand, especially in terms of export markets, this growth is set to continue.

We are well aware that none of this would have been possible without the ongoing commitment of Pr Denis Vivien, Dr Cyrille Orset and Dr Denoit Haelewyn, and would like to take this opportunity to extend our heartfelt thanks to them.

The University of Caen, the Urban Community of Caen and the BPI have also been instrumental in supporting and enabling this public/private partnership. Last but not least, we’d like to thank all the businesses that have placed their trust in us, returning with new projects. Nothing is more rewarding to us than your satisfaction!

L’article Now we are 4! est apparu en premier sur ETAP-LAB.

SYNCROSOME provides frozen or fixed slices of different tissues mounted on slides  from several preclinical models.

PAH models (Monocrotaline or SuHxNx)

• LUNGS and HEART (right and left ventricle)
• PLASMA samples

HEART FAILURE models (Isoproterenol or Myocardial infarction)

• HEART (right and left ventricles)

PARKINSON models (6-OHDA and Lactacystine):

• BRAIN

ASTHMA models (OVA and HDM):

• LUNGS

LPS-INDUCED LUNG INFLAMMATION model

• LUNGS and BRONCHO-ALVEOLAR lavage
• PLASMA

L’article New services from SYNCROSOME est apparu en premier sur ETAP-LAB.

We are very pleased to be sharing this poster.

AAIC POSTER

If you have any questions about our results, we’d be delighted to discuss them with you.

Contact Us

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the “FEDER-FSE Lorraine et Massif des Vosges 2014-2020” operational programme.

L’article The ETAP-Lab poster presented at AAIC is available online est apparu en premier sur ETAP-LAB.

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the “FEDER-FSE Lorraine et Massif des Vosges 2014-2020” operational programme.

L’article New Alzheimer’s model in the aged mouse: come and meet us at AAIC 2021 est apparu en premier sur ETAP-LAB.

#alzheimer #DrugScreening #microfluidics #neuroscience

L’article ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity est apparu en premier sur ETAP-LAB.

The SYNCROSOME team is delighted to welcome a cohort of young male ferrets. As the gold standard for emetic assessment, ferret is the well-established animal model of emesis, known for the high sensitivity of its vomiting reflex.

Two experimental designs can be performed:
– Safety evaluation by comparing your compound with a PDE4 inhibitor (Roflumilast or Rolipram)
– Study efficacy of your compound on Roflumilast emesis-nausea model induced compared with anti-emetic agents
In both protocols, the number of episodes of retching and vomiting and nausea-like behaviors will be assessed.

Sandra ROBELET, the CSO and Guénaëlle CANET, the Gastroenterology study director will be happy to respond to all your requests, questions or comments!

You can contact us via our mail: dvpt@syncrosome.com.

L’article The next Emesis/Nausea Session in ferret est apparu en premier sur ETAP-LAB.

We are looking forward to meeting you at this event!

L’article Sharing experiences about preclinical models and probiotics! est apparu en premier sur ETAP-LAB.

Please feel free to contact us to schedule a video conference.
We’re hoping to meet you soon!

L’article Meet us at the World’s Largest Virtual Partnering Experience! est apparu en premier sur ETAP-LAB.

Open space, relaxation/catering room, meeting room, laboratory with two separate animal facilities with several conventional accommodation areas for rodents and ferrets in 2 different buildings with its own equipped laundry. The laboratory contains 4 equipped surgery rooms with gaseous anaesthesia, one dedicated room for behavioural tests, 3 areas dedicated for experiments and awaking/specific care of animals, one room for preparation of compounds and solutions, one echocardiographic room, one space dedicated for our 2 hypoxic chambers, and one room for our metabolic cages and our new automatic whole body plethysmography system.

SYNCROSOME can manage more than 10 preclinical studies in the same time in CNS, Metabolic Disorders, Gastroenterology, Cardiovascular and Respiratory fields. We offer zootechnical services for 2 other companies.

L’article SYNCROSOME… lab Extension !!! est apparu en premier sur ETAP-LAB.

L’article Bio Digital: Meet us at the World’s Largest Virtual Partnering Experience! est apparu en premier sur ETAP-LAB.

As announced a few weeks ago, we evaluated the effects of AβO on synaptic function and cell survival. Quantification of protein expression in the hippocampus 18 days after intracerebral administration showed disruption to synaptic function (PSD-95) and apoptotic signalling in brain tissue.

The results obtained during our R&D project allowed us to develop a new model of early-stage Alzheimer’s disease, based on AβO toxicity. Thanks to ETAP-Lab’s unique expertise, this toxicity has been demonstrated in vitro (in primary neuronal cultures) and in vivo (in aged mice). AβO causes increased neuronal death in vitro, and cognitive impairment and biological changes that are characteristic of AD in vivo. The effects induced by AβO are sensitive to reference molecules, reducing cell death in vitro and improving cognitive performance in vivo.

The AβO and associated models ETAP-Lab now offer make it possible to evaluate – with strong scientific added value – the efficacy and therapeutic potential of molecules against Alzheimer’s disease, both in vitro and in vivo.

Please contact our team of specialists for more information on this new model.

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the “FEDER-FSE Lorraine et Massif des Vosges 2014-2020” operational programme.

L’article Alzheimer’s Disease – a new preclinical model #2 est apparu en premier sur ETAP-LAB.

We have shown that memory disorders induced by A-Beta oligomers could be significantly reduced by this symptomatic treatment of Alzheimer’s disease. This strengthens the pharmacological validity of our model. In addition, we have once again shown the reproducibility of our model.

We have shown that the deleterious effects on memory induced by the administration of A-beta 1-42 are significantly reduced in the object recognition test. Animals in the ABO group show poorer memory performance than animals in the Vehicle group, yet the memory performance of animals in the ABO-DPZ group is comparable to that of the Vehicle group (Fig 1a). The results obtained in the Morris water maze test are consistent with these findings; the animals in the Vehicle and ABO-DPZ groups improved their access time to the platform, showing a preference for the area close to the platform during the Probe Trial, whereas the animals in the ABO group showed poorer memory performance than the Vehicle group (Fig 1b).

Figure 1: Graphic representation of memory performances in  a)Novel Object Recognition test and  b) Morris Watermaze

These replicated results show that the administration of DZP can mask the effects of the ICV injection of ABO, restoring the animals’ ability to learn  in both a short-term memory (NOR) testand a long-term spatial memory (MWM) test

We will soon be sharing our biological analysis results with you! To keep up with the latest news on this, please follow our linkedin ETAP-Lab page.

Should you require any further information, please feel free to contact us .

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the operational programme “FEDER-FSE Lorraine et Massif des Vosges 2014-2020”

L’article Alzheimer’s Disease – a new preclinical model est apparu en premier sur ETAP-LAB.

By joining forces with BB@C, STROK@LLIANCE and ETAP-Lab are taking another step forward in their commitment to ensuring that the drugs of the future are the outcome of high-quality research! Sharing the single founding principle of translational research, we hope that this partnership will enable us, more than ever before, to bring all our preclinical expertise in Stroke – and in Neuroscience more broadly – to contribute to the development of new therapeutic solutions.

L’article BB@C: a new translational research institute for the clinical solutions of tomorrow – in partnership with STROK@LLIANCE and ETAP-Lab est apparu en premier sur ETAP-LAB.

This system allows to obtain reliable results particularly for our model of citric acid-induced cough in guinea pigs thanks to an automatic assessment of cough. The FinePointe Software utilizes a specific algorithm to count cough and easily distinguished them from sneezes, augmented breaths and movements. The chamber is furthermore patented with a system of reduction of the ambient noise (Halycon). Outside air movements (door opening, engineer coughing…) will not impact the tracings. The system has an automatic chamber calibration for better accuracy. Finally, nebulization rate of citric acid is well controlled as well as the condensation in the chambers. 

Thanks to this advanced technology, the efficacy of a candidate compound can be assessed with more predictability and quality acquired data. Moreover, our cough model is pharmacologically validated. The mean number of coughs in animals treated with the reference compound (codeine) is significantly reduced in comparison to animals treated with vehicle (see data below).

L’article New whole-body plethysmography system (Buxco, DSITM) est apparu en premier sur ETAP-LAB.

After several months’ development, several replicated studies show that oligomers of A-beta peptides (whose neurotoxicity in vitro is well documented), induce cognitive deficits in object recognition test and Morris watermaze in the weeks following intracerebroventricular injection in 18-month-old mice.

We have shown that the administration of A-beta 1-42 oligomers leads to significant memory impairment in the object recognition test: while animals in the vehicle group show a significant preference for the new object, animals in the ABO group explore known and unknown objects indiscriminately (Figure 1a). The results obtained in the Morris water maze test point to the same conclusion; whereas animals in the Vehicle group improved their access time to the platform and showed a preference for the area close to the platform during the Probe Trial, the animals in the ABO group showed a significant deficit in both learning and information recall (Figure 1b).

Figure 1: Graphic representation of memory performances in  a)Novel Object Recognition test and  b) Morris Watermaze

These results, which have been replicated, show that the ICV injection of ABO is capable of altering memory function in both a episodic-like memory test (NOR) and a long-term spatial memory test (MWM).

Pharmacological validation tests were undertaken following an initial phase that involved removing technical and scientific barriers and characterizing the model.

We will soon be sharing the first results obtained using donepezil!

To keep up with our latest news, just follow the ETAP-Lab page.

This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the “Region Grand-Est” and the European Union through the operational “FEDER-FSE Lorraine et Massif des Vosges 2014-2020” programme.

L’article New model for Alzheimer’s Disease – First batch of data! est apparu en premier sur ETAP-LAB.

The two finished products are Probid and Probians and contain two strains of probiotics for which the following claims are now approved:

• Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 may contribute to the reduction of feelings of anxiety in healthy individuals.
• Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 contribute to the reduction of gastrointestinal complications (such as abdominal pain and nausea/vomiting) brought on by light to moderate stress in healthy individuals.

These two strains have been marketed in various countries for the last decade under the name Probio’Stick and now rebranded as Cerebiome® (Lallemand Health Solutions). Made from the same two strains of bacteria, this was hitherto the first and only probiotic to have health claims for the gut-brain axis approved, in this case by Canada’s Natural and Non-Prescription Health Products Directorate (NNHPD).

10 years after we predicted the beneficial effects of a probiotic mixture on mood in rodent models for the Rosell-Lallemand Institute, the resulting psychobiotics formulations are approved for the Brazilian market. #OneStepAhead

The positive effects of both strains have been demonstrated in our laboratory. Tested in our preclinical models of mood disorder, we established proof of efficacy in animals back in 2010, predicting these psychobiotic properties prior to clinical evaluation.

ETAP-Lab has been using preclinical studies to support R&D in the health-nutrition industry for 30 years now. By evaluating their efficacy and innocuity in rodents, we have contributed to the development of hundreds of compounds, many of which are now on the market.

Messaoudi et al, 2010; Br J Nutr. :

https://pubmed.ncbi.nlm.nih.gov/20974015/

Messaoudi et al, 2011; Gut microbes: https://pubmed.ncbi.nlm.nih.gov/21983070/

L’article Approval for the first psychobiotics: ETAP-Lab is proud to have played a role est apparu en premier sur ETAP-LAB.

We were able to show that the accelerated healing achieved by use of the innovative UrgoStart dressings was linked to faster and denser reconstruction of the local vascular network, in comparison with control conditions in rats. These results, invaluable for URGO laboratories, have made it possible to demonstrate histological modifications supporting the effects of UrgoStart.

Back in 2010, ETAP-Lab had already conducted the preclinical studies showing the beneficial effects of the UrgoStart dressing on healing. Continuation of this work in the clinical setting allowed URGO laboratories to win the Prix Galien 2018 in the Medical Device category.

For further information, please see the full poster here.

ETAP-Lab has been evaluating the effectiveness of medical devices on behalf of its dermatology clients for 20 years now.

Find out more

L’article EWMA: Presentation of the results of work we conducted for URGO laboratories est apparu en premier sur ETAP-LAB.

BNDF applied at the same time as tau oligomers significantly and reproducibly reduced cell mortality.

Incubation of cortical neurons with Tau monomers, TauO and TauO+BDNF. TauO decreased quite significantly cell viability (*; p<0.01), while monomers showed no neurotoxic effect. Incubation with BDNF significantly reversed TauO-induced neurotoxicity (#; p<0.01). Data are expressed as percent of vehicle (set at 100%) and represent the mean ± SD. (N=3, n=12).

This tauopathy model is now available for the screening of your compounds. This enhances our range of in vitro services in the field of neurodegenerative diseases.

Characterization of our model will continue with an exploration of the effects of tau oligomers on different signalling pathways.

Keep up with our in vitro activity by following our  LinkedIn page.

L’article Our tau oligomer toxicity – a new tool for drug screening est apparu en premier sur ETAP-LAB.

Promising and repeatedly replicated data show that tau oligomers exhibit dose-dependent toxicity that is not observed with equivalent monomer concentrations. At high concentrations, the oligomers completely destabilise the neurons, leading to a rapid mortality rate of 100%.

Now that the main technical obstacles have been overcome, a validated model for pharmacological screening should be ready soon. The next step is to evaluate some reference compounds. The first BDNF results are expected within a couple of weeks.

Keep up with our in vitro activity by following our ETAP-Lab page Follow us on LinkedIn

L’article Tau oligomer toxicity – our first data! est apparu en premier sur ETAP-LAB.

We will be at BIO Japan 2020 throughout, from 14 to 16 October. Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory’s activities in preclinical Neurology, Dermatology and Nutrition-Health.

Please feel free to contact us to schedule a video conference.

We’re hoping to meet you soon!

L’article BIO Japan 2020 est apparu en premier sur ETAP-LAB.

A New Diagnostic Tool for Stroke

Time is Brain. Speed of diagnosis is a critical issue in the treatment of stroke patients. At present, only MRI brain imaging can provide the information needed to make a reliable diagnosis, so that treatment can be tailored to the patient’s situation. In the emergency context, the geographical availability and usage rate of MRIs remains a major obstacle. If we could accelerate diagnosis of hemodynamic abnormalities to distinguish thrombosis from haemorrhage through the use of a convenient and accessible tool, this would represent a significant advance in patient care. It would both improve patient chances of survival and reduce the impact of stroke on long-term functional deficits and quality of life.

The use of functional ultrasound imaging (fUS) opens up precisely such application perspectives. This innovative imaging technique makes it possible to quantify cerebral blood flow with unequalled spatial and temporal resolution, and calculate the volumes of ischemic brain tissue.

This study is the first proof-of-concept of the use of fUS to predict the effectiveness of recanalization in a mouse thromboembolic stroke model. We have achieved this by measuring the impact of a fibrinolytic treatment (rt-PA, Alteplase, BI, Germany) on the evolution of stroke, using two innovative fUS methods (ultrafast ultrasound and ultrasound localization microscopy) in combination with MRI imaging (7T-MRI).

Figure 1: Comparison of ischemic volumes 2 hours post-stroke (CUS t+2h) and 24-hour MRI lesion volumes (MRI t+24h) at different levels of coronal slice versus Bregma (β).

fUS imaging enabled us to monitor ischemia-induced brain hypoperfusion in mice, showing that the ischemic volume measured 2 hours post-stroke does predict the size of the ischemic lesion measured by MRI, 24 hours post-stroke. In addition, partial reperfusion was measured at the same time in mice treated with rt-PA, and also predicts reduced final infarct volume in these mice.

This innovative tool therefore offers high diagnostic value in the clinical management of stroke. It is also of interest for conducting preclinical studies complementary to Doppler technologies (Doppler laser and Doppler speckle) and MRI, both of which provide only semi-quantitative data and are limited in their spatial and temporal resolutions.

We are therefore convinced that ultrafast ultrasound imaging and ultrasound localization microscopy are future-oriented tools for long-term non-invasive monitoring of cerebral blood flow in both clinical and preclinical settings.

L’article A first co-publication from PhIND and STROK@LLIANCE est apparu en premier sur ETAP-LAB.

Have your preclinical R&D projects fallen behind schedule during lockdown?

Every industrial activity has been knocked sideways by the COVID-19 emergency – and healthcare R&D is no exception.

Because we’ve been busy preparing the ground for the recovery ever since the start of lockdown, we are ready to support you as best we can in the intense catch-up period that is to come.

Many of the studies we helped plan during lockdown are already under way. We are glad to see our customers continuing to place their trust in us, safe in the knowledge that our services are maintaining the same high standards of quality, speed and satisfaction as usual.

If your preclinical expertise needs are on a tight schedule, our team is on hand to help identify the best way forward, together!  

Contact us

L’article Let’s get back on track together! est apparu en premier sur ETAP-LAB.

Thanks to everyone we met – we really appreciated the quality of our discussions, and are as excited as ever to be working alongside you on your #stroke #preclinical projects.

Thanks also to CCI France and Business France, for supporting the export of innovative French CROs and biotechs.

L’article B2B meetings at BIO-Digital est apparu en premier sur ETAP-LAB.

Thanks also to Business France and CCI France, for supporting the export of innovative French biotechs and CROs.

L’article B2B meetings at BIO-Digital: A fast-paced week filled with opportunities! est apparu en premier sur ETAP-LAB.

Please feel free to reach out if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO-Digital, 8-12 june est apparu en premier sur ETAP-LAB.

Please feel free to reach out if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO-Digital, 8-12 june est apparu en premier sur ETAP-LAB.

We hope that you are not being too hard hit by the current crisis, and that you and your family and friends remain healthy.

Like many others, we have reorganized our production schedule to ensure continuity of service while keeping our team safe. Although things may take a little longer, our team is standing by to conduct your studies to the high-quality standards that underpin our reputation.

This period of uncertainty also offers an opportunity for us to reflect on our R&D strategy and be proactive with regards to client projects.

We find ourselves with more time to think ahead – and so do you.

As always, our experts are here to offer support with your preclinical expertise challenges.

Please do feel free to get in touch and contact us here.

Wishing you all the best in these difficult times! 

L’article COVID-19: Business Continuity est apparu en premier sur ETAP-LAB.

Like many others, we have reorganized our production schedule to ensure continuity of service while keeping our team safe. Although things may take a little longer, our team is standing by to conduct your studies to the high-quality standards that underpin our reputation.

This period of uncertainty also offers an opportunity for us to reflect on our R&D strategy and be proactive with regards to client projects.

We find ourselves with more time to think ahead – and so do you.

As always, our experts are here to offer support with your preclinical expertise challenges.

Please do feel free to get in touch and contact us here.

Wishing you all the best in these difficult times! 

L’article COVID-19: Business Continuity est apparu en premier sur ETAP-LAB.

Indeed, ETAP-Lab has just signed a major contract to assess the effects of a dermatological pharmaceutical treatment currently in development.

Atopic dermatitis is a common skin condition that mainly results in redness, lesions and intense itching (pruritus). For patients, it can affect everyday life severely enough to cause anxiety and depression.

15-20% of all children, and 1-3% of all adults worldwide are concerned, and there is a steady increase in prevalence. Asian and black people are more likely to be affected than white people.

Contact us

L’article ETAP-Lab’s dermatology activity keeps growing: our first project with a US-based company est apparu en premier sur ETAP-LAB.

It is a real pleasure for us to see our brand building value.

Having already secured trademark protection in Europe, ETAP-Lab is proud to announce that the Japanese patent office has now approved our application to register the STROK@LLIANCE trademark.

We decided to include an image of the official document because, in addition to its legal value, it is beautifully decorated with motifs featuring peacocks and bamboo!

Contact us

L’article STROK@LLIANCE – now a registered trademark in Japan est apparu en premier sur ETAP-LAB.

It is a real pleasure for us to see our brand building value.

Having already secured trademark protection in Europe, ETAP-Lab is proud to announce that the Japanese patent office has now approved our application to register the STROK@LLIANCE trademark.

We decided to include an image of the official document because, in addition to its legal value, it is beautifully decorated with motifs featuring peacocks and bamboo!

Contact us

L’article STROK@LLIANCE – now a registered trademark in Japan est apparu en premier sur ETAP-LAB.

While this old molecule is well known as a bronchial fluidizer, it is not generally thought of as having anything to do with strokes. However, Prof. Vivien and his team have found that similarities exist between blood clots and nasal secretions. As the l’Express article reports, Prof. Vivien states that they “are all made up of large close-structural proteins that form a mesh, with white and red blood cells trapped on one side and nasal secretions on the other”. More specifically, the Van Willebrand factor that enables platelet aggregation has structural similarities with the mucins present in mucus.

Preclinical trials have shown that NAC has the ability to dissolve platelet clots in human blood samples in vitro, as well as reduce the cerebral injury induced by ischemic stroke in mouse models that are resistant to current thrombolytic therapy.  In this way, “even clots resistant to the best available treatments have been dissolved”.

In spring 2020, Prof. Vivien and his team will begin a clinical trial with 200 patients across 10 hospitals. This project holds out hope for better stroke management during the acute phase that is the leading cause of severe acquired disability, worldwide. In addition to the ready availability of this molecule, the likelihood of successful development is enhanced by the fact that we are already familiar with its side effects and how to control them.

All the know-how and methodologies implemented for the preclinical characterization of NAC have been transferred to STROK@LLIANCE, which is the only CRO 100% dedicated to preclinical stroke. Find out more about all our models and services on our website.

Contact us

L’article A new stroke treatment developed by our academic partner is featured in the French newspaper l’Express. est apparu en premier sur ETAP-LAB.

Starting in 2020 with inavea pure acacia, an all-natural dietary fiber sourced from carefully selected acacia trees, Nexira offers a high digestive tolerance and a prebiotic effect.

Preclinical studies conducted by ETAP-Lab have proven the health benefits of other products on offer from Nexira, world leader in acacia. Nexira has been able to develop a range of products for weight management – such as CactiNea™, combining prickly pear and acacia for a diuretic effect, and ID-alG™, a brown seaweed extract for weight loss, thanks to several preclinical studies performed by ETAP-Lab and published in international scientific journals (Bisson et al., 2010; Terpend et al., 2012).

Contact us

L’article Nexira invites trusted service provider ETAP-Lab to its inavea™ launch est apparu en premier sur ETAP-LAB.

For the end of 2019, join us at the BioFIT event in Marseille, France

Syncrosome invites you to visit us at BioFit, December 10th to December 11th 2019, in Marseille, France.

Emmanuelle Bettendorf, our Business Developer, and Sandra Robelet our Scientific Manager, would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

Please contact us to organize a 1-2-1 meeting in Marseille !

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastroenterology.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Biofit 2019, Marseille est apparu en premier sur ETAP-LAB.

Etap Lab

Our experts Dr. Jean-François BISSON (VP) and Dr. Nicolas Violle (CEO) will present ETAP-Lab’s services in the fields of preclinical Dermatology with our partner CYCERON.

ETAP-Lab has a track-record of success in the testing of medical devices in the field of Dermatology, such as dressing, plaster and bandage.

Strok@allaince

Our expert Dr. Nicolas Violle (CEO) will present Strok@lliance’s services in the field of stroke preclinical research. Our partner CYCERON, represented by Dr. Benoit Haelewyn, will also be present during this event.

By taking advantage of the CYCERON facilities, STROK@LLIANCE accesses such cutting-edge technologies as 7T-MRI and PET-scan.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

Contact us

L’article Meet us at MEDICA in Düsseldorf, 19 November est apparu en premier sur ETAP-LAB.

Following a decision taken by the Ministry of Higher Education and Research, Syncrosome has been awarded the authorization of « Crédit Impôt Recherche » in France (Research Credit).

This authorization is accorded for the years 2019, 2020 and 2021.

The French Ministry thereby recognizes that Syncrosome is a fully optimized company dedicated to conduct your preclinical Drug Development. 

Syncrosome CIR accreditation has been renewed for more than 10 years now, Syncrosome has worked as a preclinical CRO accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR). Our recognition procures a significant financial benefit for French companies wishing to pursue their R & D work in Cardiovascular, Central Nervous System, Respiratory or Gastrointestinal field with Syncrosome.
This authorization is accorded for the years 2019, 2020 and 2021

L’article CIR Renewal for Syncrosome laboratory and animal facilities est apparu en premier sur ETAP-LAB.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

Contact us

L’article Meet us at BIO Europe in Hamburg, 11-13 November est apparu en premier sur ETAP-LAB.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

L’article Meet us at BIO Europe in Hamburg, 11-13 November est apparu en premier sur ETAP-LAB.

We are very happy and proud to announce that we have now extensively validated the following in vitro pharmacological models:

• A model of Alzheimer’s disease: challenge with beta-amyloid 1-42 oligomers in rat primary cortical neuron culture;
• A model of Parkinson’s disease: challenge with alpha-synuclein oligomers in rat primary cortical neuron culture.

Batch-to-batch oligomer production reproducibility has been controlled, confirming the oligomeric form of the proteins contained in our preparations. The toxic dose 50 has been evaluated for each preparation. Then, in vitro assays showed very good repeatability and reproducibility with BDNF used as a reference drug. A newsletter is in preparation with summarized results.

These in vitro models are now available for mild throughput screening of your drugs. Feel free to contact us if you would like any further information.

Contact us

L’article In vitro services are ready to test your drugs for neurodegenerative diseases! est apparu en premier sur ETAP-LAB.

Since 2016, Syncrosome improves it’s expertise in the Cardiovascular field by developing animal models in Heart Failure (Chemical or Surgical induction), in Ischemia Reperfusion Injury, in Pulmonary Arterial Hypertension (Monocrotaline and Sugen model) but also by implanting new devices like the Echocardiography which offers longitudinal follow-up of the animals and add new functional and morphological biomarkers to our cardiovascular studies.

You can ask us the poster via the address : dvpt@syncrosome.com

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :

• Central Nervous Sytem, 

• Cardiovascular and Metabolic disease, 

• Respiratory,

• Gastroenterology.

• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article New preclinical models of Heart Failure presented at the last edition of the GRRC est apparu en premier sur ETAP-LAB.

Emmanuelle Bettendorf, Account Manager in Syncrosome since 2009, will attend this international congress and will present the preclinical’s activities of Syncrosome to the 700 delegates coming from Biotech and Pharma environment.

A few words about Syncrosome: 

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studiesin several therapeutic areas :
  • Central Nervous Sytem, 
  • Cardiovascular and Metabolic disease, 
  • Respiratory,
  • Gastroenterology.

Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome will attend the 19th Annual Biotech in Europe Forum (Basel, 24th to 26th of October 2019) est apparu en premier sur ETAP-LAB.

Come and meet Syncrosome at #BIO2019 booth #2109.

Syncrosome invites you to visit us at BioConvention, June 3rd to June 7th 2016, in Philadelphia, USA.

Emmanuelle Bettendorf, our Account Manager would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

#BIO2019 #SouthOfFranceAtBIO19

L’article Syncrosome will attend the Next BioConvention in Philadelphia, USA est apparu en premier sur ETAP-LAB.

The clinical studies were performed after ETAP-Lab showed a significant benefit of Pep2Dia. Indeed, when administered 15 minutes before a sugar shot in db/db mice, Pep2Dia significantly decreased blood glucose (AUC kinetic) by 33%. Blood sugar concentration was monitored during the 2h following the glucose shot.
ETAP-Lab studies made the in vivo proof-of-efficacy, while helping to select compounds and choose dosing. It underlines the great interest of preclinical studies for Health-Nutrition industry to de-risk the development of innovative bioactive ingredients.

More about ETAP-Lab preclinical services in Health-Nutrition.

L’article Clinical evidence confirms Pep2Dia effects on postprandial glycemia in prediabetic subjects est apparu en premier sur ETAP-LAB.

Thanks to its CNS expertise our CNS Study Monitor, Dr. Delphine Revy, will present several results on Symptomatic and biochemical assessment of an antidyskinetic compound in a L-DOPA induced Dyskinesias rat model.

A few words about Syncrosome: 

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studiesin several therapeutic areas :
  • Central Nervous Sytem, 
  • Cardiovascular and Metabolic disease, 
  • Respiratory,
  • Gastroenterology.

Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome at the next NeuroFrance Congress in Marseille est apparu en premier sur ETAP-LAB.

Oral presentation by Pr. Denis Vivien during the 2nd Strok@lliance annual meeting, June 5^th 2018, at the Maison de la Chimie, Paris.

Pr. Vivien presents new animal models and strategies to improve our preclinical research.

L’article About the future of translational stroke research est apparu en premier sur ETAP-LAB.

L’article Microbiome & Probiotics Series est apparu en premier sur ETAP-LAB.

ETAP-Lab launches a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases

ETAP-Lab proudly announces the launch of ETAP-Cell: a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases. The creation of this activity has been made possible by the recruitment of Dr Ahmad Allouche (former Head of Biology at SynAging) who is placing his unique expertise in the solubilization and stabilization of oligomeric proteins (AβO, αSO and TauO) at the disposal of ETAP-Lab.

As a first step, ETAP-Cell will focus on validating the reproducibility of its tests on cultures of primary rat neurons. The initial results are expected in May 2019.

The implementation of other models using other preparations (αS fibrils, TDP43 oligomers) will follow. At the same time, corresponding tests will be validated in vivo in mice.

In the medium term, in vitro tests in the fields of stroke and multiple sclerosis are also planned, to complement the unique and outstanding in vivo services offered by ETAP-Lab – thanks in particular to the public/private partnerships it has established with internationally renowned academic research teams.

Until then, the ETAP-Lab team is receptive to hearing about your needs and expectations, the better to integrate these into the solutions being developed.

With ETAP-Cell, ETAP-Lab is expanding its range of preclinical services, while maintaining the concern for quality and advice for which it is so well-respected. Our objective is also to participate in the ongoing collective effort within the pharmaceutical industry to offer models having high translational value, while reducing the number of animals used for experimentation. This is why ETAP-Lab already plans to invest in the development of innovative tests based on human pluripotent stem cell cultures (h-IPSCs). N. VIOLLE, CEO

L’article ETAP-Cell: New in vitro services in Neurology est apparu en premier sur ETAP-LAB.

Ischemia-reperfusion injury:
Recent clinical data challenge the translational value of mechanical MCAO models of stroke in rodents

Ischemia-reperfusion injury has been hypothesized to play a major role in the physiopathology of acute stroke since it has been demonstrated that abrupt reperfusion induces secondary brain damages responsible for up to 70% of the final ischemic lesion size in rodents.

However, such a critical role for abrupt reperfusion on the ischemic injury has never been clearly demonstrated in human. Indeed, clinical data were still lacking up to recently. It is of importance considering that mechanical ischemia-reperfusion with a monofilament has been considered as a gold-standard model of stroke for decades.

That’s why Strok@lliance‘s academic partner (PhIND laboratory, Caen) reanalysed data from Aspiration vs Stent Retriever for Successful Revascularization (ASTER) clinical study to evaluate cerebral infarct progression after abrupt reperfusion in thrombectomised patients.

The results, recently published in the journal Stroke, did not evidence any lesion growth 24h after complete reperfusion in most patients.

This discrepancy between clinical and preclinical pathophysiologies question the translational value of the mechanical ischemia-reperfusion model in rodents and should be considered during preclinical evaluation of neuroprotective strategies. In particular, it indicates that this model is not a translational model of thrombectomy nor a suitable model to test neuroprotective agent efficacy during the acute phase of stroke.

It underlines the urgent need for more translational models. That’s why we, at Strok@lliance, are committed to provide innovative ischemic stroke models to support the development of new drugs.

Link toward the article

L’article STROK@lliance – Expert Opinion #1 est apparu en premier sur ETAP-LAB.

Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease models, and more specifically Parkinson Disease (PD).

This department is also focused on CNS-PK with relevant tools as microdialysis and CSF sampling.

I am pleased to inform you that Syncrosome will attend the Translational Neuroscience Congress, in Paris, France on January, 25th 2019.

The idea for Syncrosome is to Keep up to date on Parkinsonian animal models and to evaluate the new trend for 2019 and later…

Key topics will be discussed:

• Translational research on neurodegenerative disease
• Imaging & RMN spectroscopy 
• Advances in Animal model

and we’ll have the chance to exchange with Key Biotech and Pharma companies like Lundbeck, Prexton, Amabiotics, Theranexus … and Center of Excellence in Neurodegenerative diseases like DHUNE…

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome & the Translational Neuroscience Congress est apparu en premier sur ETAP-LAB.

• Strok@lliance is proud to count new clients from mid-size to top 10 pharma companies.

• Several new tailor-made models have been added to our catalogue according to customers request including:

→ A double autologous blood injection in cisterna magna, a complex model of subarachnoidian hemorrhage in rat.

→ Models of ischemia-reperfusion in juvenile rats (28 days) enabling Strok@lliance to predict the effects related to drug administration on children.

• Strok@lliance obtained a grant from French research ministry to start a CIFRE Thesis. The Thesis will start in spring 2019 and will focused on the refinement of our thrombin-induced stroke models by the addition of comorbidities (aging, hypertension, diabetes…).

• Strok@lliance team is growing with the recruitment of new technicians, empowering us to carry out more and more projects with the same level of quality and efficiency.

After these past two years, Strok@lliance is pursuing its objective of becoming a reference as the preclinical CRO dedicated to stroke with an increasingly number of projects planned for 2019.

Our team is grateful for the trust customers placed in us to design and validate stroke models, as well as to carry out their pre-clinical studies. We are committed to provide services of quality and are constantly evolving to answer customer specific demands.

L’article Annual Report of 2018 est apparu en premier sur ETAP-LAB.

• A new atopic dermatitis model, the DNCB-induced model in Balb/c mice, has been developed with effective studies already in progress.

• New studies for the account of TEMESIS have been performed showing remarkable effects of their lead TEM1657 drug candidate on Psoriasis and results have been presented in different congresses. Different formulations of their product remaining to be characterized.

• Jean-François Bisson participated to the World Preclinical Congress in Lisbon to discuss chronobiology and animal welfare, a key point of our activity. Indeed, ETAP-Lab controls reverse light cycle and behavioral animal tests are run during their activity phases in order to have a thorough follow-up of the animal but also to monitor the possible side effects of a product.

• ETAP-Lab has acquired new equipment including a C-Cube camera allowing to make reproducible pictures in very high quality, which is essential for the follow-up for the development of dermatological diseases.

• ETAP-Lab established a collaboration with the European Institute of Antioxidants to measure total antioxidant capacities in skin tissue and fluids using PAOT^© Technologies. Now, ETAP-Lab can pursue studies on antioxidant compounds administered locally or orally for other dermatological conditions such as vitiligo, extending further research possibilities.

• A metagenomic project for the analysis of bacterial strains at the cutaneous level before (healthy mice) and after pathology induction (psoriasis, atopic dermatitis, skin inflammation) is in progress. 

• Some projects and studies will be launched in 2019, including:

 → A preclinical study aiming at evaluating the efficacy of a miniaturized smart system built up to improve wound healing by light stimulation within the framework, the European project “MEDILIGHT”.

→ A study on skin explant models in animals for severe burns or long-term healing. Building the tests to evaluate explants’ parameters is planned for 2019.

• Several new models are in progress and envisaged for 2019, including:

→ Atopic dermatitis mice model with mite induction, only available in Asia at the present time.

→ Vitiligo, acne, rosacea and alopecia mice models.

Through this year, ETAP-Lab has been able to prosper in the dermatology field with various projects, models and collaborations completed over the world. The main objective in 2019 is to develop new models/study methods to answer customer needs as well as future therapeutic issues. 

We are grateful for the trust that customers have placed in us to design and validate new models, as well as to carry out their pre-clinical studies. We are committed to always provide services of quality, rigor, ethical compliance, reactivity and are delighted to constantly evolve according to customer specific demands.

Annual Report of 2018

L’article Annual Report of 2018 est apparu en premier sur ETAP-LAB.

Through an internal and external Audit of the OFC (the French Certification Organization): quality assurance, control and monitoring procedures have been carried out to attest to the quality of our services.

By being accredited, our company is insuring the customers to meet their expectations by the quality of its management system in the following areas: consulting, advising and expertise of studies in the field of in vitro and in vivo preclinical research.

L’article Strok@lliance is now certified ISO 9001 (2015 Edition) est apparu en premier sur ETAP-LAB.

If you are searching for a reliable partner for in vivo preclinical studies, please contact Jean-François BISSON at: jfbisson@etap-lab.com and you could meet there at the end of November. For more information about the meeting click here.

L’article ETAP-Lab participation at the World Preclinical Congress Europe 2018 in Lisbon est apparu en premier sur ETAP-LAB.

The 6^ThDrug Discovery Innovation Programme will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Frankfurt (Germany) from 29 to 30^thof October. This conference will offer a complete programme focusing on preclinical animal models, breakthrough technologies :

• Target engagement
• Advances in medicinal chemistry
• Pre-clinical pharmacokinetics
• Modern approaches for drug design
• Role of AI in drug discovery
• Open innovation…

Syncrosome is happy to host a booth and participate to the networking event.

Syncrosome provides a complete service in Preclinical Efficacy testing from in vitro to in vivo testing and trough biodisponibility studies on rodents and non-rodents species. Our multiple skills, combined with scientific background and 18 years of expertize results in fruitful collaboration with Pharmaceutical and Biotech. Companies.

For additional information on our conference participation or to schedule a meeting with Emmanuelle Bettendorf, please email us.

L’article Syncrosome will be pleased to meet you at Frankfurt during the 6th DDIP Congress est apparu en premier sur ETAP-LAB.

Through an internal and external audit of the OFC (the French Certification Organization), quality assurance, control and monitoring procedures have been carried out to attest to the quality of our services.

By being accredited, our company ensures customers that their expectations are met through the quality of its management system in the following areas: consulting, advising and expertise of studies in the field of in vitro and in vivo preclinical research. This step also constitutes an extension of the previous certification, as all ETAP-Lab activities are now included.

In addition, Strok@lliance, the co-created brand of ETAP-Lab dedicated exclusively to stroke, is now included in this certification for the first time.

Link to the certification

L’article ETAP-Lab has been upgraded to the ISO 9001 certification (2015 Edition) est apparu en premier sur ETAP-LAB.

Link to the article

L’article Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke est apparu en premier sur ETAP-LAB.

Researchers from Europe but also from other non-European countries (USA, India, Jordan, Indonesia…) participated to this congress as well. Therefore, most recent advances have been presented concerning the diagnosis and the treatment of several pathologies including wound healing, psoriasis, atopic dermatitis, acne, facial rejuvenation and skin bleaching.

A focus on the use of bioengineered skin for preclinical and clinical applications has also been made by Pr. Marcela Del Rio from the University Carlos III of Madrid.

Bioengineered skin substitutes are effectively used in a preclinical context with skin grafting in immunodeficient mice, not only to classical disease models such as psoriasis but also to address rare genetic skin diseases such as genodermatoses, xeroderma pigmentosum, epidermolysis bulbosa…, and to better understand physiological processes.

In the near future, skin tissue engineering will become a multidisciplinary science with the development of a next generation of biomimic skin substitutes.

L’article 18th Global Dermatology Congress October 25-26, 2018, Budapest, Hungary est apparu en premier sur ETAP-LAB.

During the conference, key opinion leaders in the field of stroke enlightened the reality of post-stroke deficit evaluation and rehabilitation in both the setting of clinical trials and medical cares. The event gathered nearly 40 participants, coming from both the public and the industry. It was also the opportunity for Strok@lliance’s team to share some innovative behavioral tests and research strategies in rodents, supporting the major impact of preclinical research on the design of clinical studies.

Follow the video release of the conferences during next weeks on strok@lliance website (sucscribe via our contact form).

Thanks again to all the attendees, see you next year for the Strok@lliance 3^rd annual meeting.

The Strok@lliance’s Team

L’article 2nd Strok@lliance annual meeting was a success! est apparu en premier sur ETAP-LAB.

Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin inflammation in mice

S. Holowacz, C. Blondeau, I. Guinobert, A. Guilbot, S. Hidalgo and J.F. Bisson
Published in Beneficial Microbes, in Press

Abstract

Oral probiotics potential for the management of dermatological diseases is vast. However, results of available studies in skin diseases, such as atopic dermatitis (AD), are inconsistent, partly because probiotic effects are strain specific. Careful selection of probiotic strains is therefore indispensable to ensure efficacy of treatment. In this study, Lactobacillus salivarius LA307, Lactobacillus rhamnosus LA305 and Bifidobacterium bifidumPI22, three strains that were previously identified for their interesting immunomodulatory properties in allergy and/or colitis models, were assessed in the prevention of chronic skin inflammation induced by repeated applications of 12-O-tetradecanoylphorbol-13-acetate in hairless SKH-1 mice. Macroscopic and microscopic evaluation of skin lesions was performed together with measurements of serum levels of interleukin (IL)-1β, IL-6, tumour necrosis factor alpha (TNF-α), IL-17, IL-22, IL-10 and IL-4. Daily oral treatment with the three strains at the dose of 1×109 cfu/day for 3 weeks limited the development of chronic skin inflammation, the effects being strain dependent. Indeed the two Lactobacillus strains significantly limited the intensity of skin inflammation both at the macroscopic and microscopic levels. Macroscopic observations were correlated to the histological observations and the resulting microscopic score. This limitation of the development of AD-like skin lesions involved the modulation of cytokine production. Treatment with the two Lactobacillus strains induced a decrease in the serum levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, IL-17, IL-22 and at the opposite an increase in the production of the anti-inflammatory cytokine IL-10 and also of IL-4. Globally, B. bifidum PI22 had lower benefits. These results obtained in mice suggest that L. salivarius LA307 and L. rhamnosus LA305 could be good candidates for preserving skin integrity and homeostasis via the modulation of the gut microbiota and that their use could be beneficial in dermatological conditions such as AD.

Publisher website

ETAP-Lab has strong experience in the field of dermatology research by developing a wide portfolio of original in vivo models.

With total transparency, our expertise and know-how include:
– Respecting chronobiology and animal well-being
– Considering chronopharmacology during treatments
– Evaluating animal behavior to confirm beneficial/ adverse effects of treatments

Want to know more ?

L’article New publication in Dermatology! est apparu en premier sur ETAP-LAB.

Dr. Nicolas VIOLLE will attend to the 3rd European Stroke Organization Conference ​ (ESOC) from 16-18 May, 2017 (Prague).

ESOC is one of the most exiting conference this year about clinical trials and developments in stroke management, treatment and prevention.
It will be the occasion for us to meet leaders from pharmaceutical industry to present STROM@LLIANCE, the new service 100% dedicated to preclinical stroke research.

Contact us from now to schedule a meeting.

L’article Meet us at ESOC 2017 est apparu en premier sur ETAP-LAB.

ETAP-Lab (Dr Nicolas Violle, President and CEO) is a well-established CRO, with more than 25 years of market knowledge.

ESRP is the offshoot of the highly-recognized INSERM unit “Physiopathology and Imaging of Neurological Disorders” (PhIND; Pr. Denis Vivien, Head of the unit). The new platform STROK@LLIANCE is fully dedicated to preclinical stroke in order to address mechanisms, diagnostics and therapeutics in stroke.

STROK@LLIANCE manages projects in the field of stroke for the pharmaceutical industry with high-skilled specialists ensuring expertise and creativity to provide high-level animal studies in a quality-controlled environment. Taking advantage of CYCERON facilities (Caen, France), STROK@LLIANCE accesses to cutting-edge technologies such as MRI, PET, Doppler and proposes fine-tuned behavioral studies.

STROK@LLIANCE offers numerous innovative and translational animal models combined with a unique package of expertise and consultancy.

STROK@LLIANCE is a unique tool designed to conduct in vivo preclinical studies on innovative therapeutic approaches to stroke (drugs/medical devices/diagnostic tools), prior to conducting them on humans.

L’article STROK@LLIANCE: a new service est apparu en premier sur ETAP-LAB.

PMID:28102110

L’article New article in mood disorders est apparu en premier sur ETAP-LAB.

L’article Press Article: In vivo preclinical research serving the food industry est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP-Lab participation to NutrEvent 2017 est apparu en premier sur ETAP-LAB.

L’article ETAP-Lab participation to ESOC 2017 est apparu en premier sur ETAP-LAB.

L’article ETAP-Lab participation to AFSTAL 2017 est apparu en premier sur ETAP-LAB.

For more information please contact us.

L’article New model in dermatology est apparu en premier sur ETAP-LAB.

L’article Kick-off meeting: STROK@LLIANCE est apparu en premier sur ETAP-LAB.

We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of Parkinson’s disease (PD). We performed a systematic literature search to identify studies that used behavioral testing to evaluate the treatment effect of unmodified MSCs in PD models. Meta-analysis was used to determine pooled effect size for rotational behavior and limb function and meta-regression was performed to explore sources of heterogeneity.

Twenty-five studies including three delivery routes, a wide range of doses, and multiple PD models were examined. Significant improvement was seen in the pooled standardized mean difference (SMD) for both rotational behavior (SMD: 1.24, 95% CI: 0.84,1.64) and limb function (SMD: 0.84, 95% CI: 0.01, 1.66). Using meta-regression, IV administration and higher dose had a larger effect on limb function. Treatment with MSCs improves behavioral outcomes in PD models.

Our analyses suggest that MSCs could be considered for early stage clinical trials in the treatment of PD.

About the article:
Riecke Jenny, Johns Katherine M., Cai Chunyan, Vahidy Farhaan Shaheer, Parsha Kaushik, Furr-Stimming Erin, Schiess Mya, and Savitz Sean I.. Stem Cells and Development. September 15, 2015, 24(18): 2082-2090. doi:10.1089/scd.2015.0127.

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Meta analysis of mesenchymal stem cells in preclinical Parkinson models est apparu en premier sur ETAP-LAB.

The 4th Microbiome R&D and Business collaboration Forum will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Amsterdam (Netherlands) from 3 to 4^th of April. This conference will offer a complete programme focusing on preclinical animal model and specific focuses :

• Probiotics and Digestive Health (Roles in in IBS management…)
• Microbiome in Health and Disease (IBD, CNS disease…)
• Skin Microbiome and Dermatology
• R&D out site the gut (Gut-brain interactions, Microbiota and COPD, Asthma…)

Syncrosome is happy to host a booth and participate to the networking event.

Syncrosome provides a complete service in Preclinical Efficacy testing from in vitro to in vivo testing and trough biodisponibility studies on rodents and non-rodents species. Our multiple skills, combined with scientific background and 15 years of expertize results in fruitful collaboration with Pharmaceutical and Biotech. Companies.

Come on our booth N°25 and visit us

• Meet Emmanuelle, your Business contact at Syncrosome since 2009
• Discover our new in vitro and vivo models
• Discuss your preclinical project with experts and save time on your project

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome at the next Microbiome & Probotics Forum in Amsterdam est apparu en premier sur ETAP-LAB.

Animal studies (rat ischemia reperfusion) indicate that the preservation of myocardium could still be accomplished through interventions that block specific processes. In particular, mitochondria have recently emerged as central players in the ischemia/reperfusion injury process. After a MI, the reintroduction of oxygen to mitochondria that have experienced a prolonged period of hypoxia can generate a burst of reactive oxygen species, which can damage mitochondrial DNA (mtDNA). These liberated mtDNA can cause harm the myocardial cells and can be one of the reasons for injury.

Recent reports indicate that elevating DNA glycosylase/AP lyase repair enzyme activity offers marked cytoprotection in cultured cells and a variety of injury models. Researchers from the University of Alabama in the USA created and measured the effect of a fusion protein (EndoIII) containing Endonuclease III, a DNA glycosylase/AP lyase, which was engineered to allow its rapid uptake into the matrix of mitochondria, on infarct size in a rat model of myocardial ischemia/reperfusion.

In a preliminary report, this protein had reduced infarct size in a mouse model of coronary occlusion/reperfusion. For the present work, this protein was tested in rat hearts to determine whether systemic administration could protect the heart from infarction resulting from myocardial ischemia/reperfusion and to provide novel information concerning its mechanism of action.

 The magnitude of EndoIII’s protection was comparable to that seen with the platelet aggregation inhibitor cangrelor, the standard of care for treatment of acute myocardial, and could further reduce infarct size in rats treated with a maximally protective dose of cangrelor. The combination reduced infarct size to 15.1 ± 0.9 % which was significantly smaller than that seen with either cangrelor or EndoIII alone. However, both those molecules were shown to use differing cellular mechanisms to act.

Indeed, according to the new findings, EndoIII protects the heart from spreading necrosis by preventing the release of proinflammatory fragments of mtDNA into the heart tissue. The researchers validated the hypothesis that mtDNA were causing inflammation in heart tissue. Infarct size doubled when the coronary vasculature was filled with mtDNA fragments during the period of global ischemia.

Additive protection was possible by adding deoxyribonuclease I (DNase I), which degrades any DNA fragments escaping into the extracellular space. While EndoIII can maintain mitochondrial integrity in many of the ischemic cardiomyocytes, DNase I can further prevent mtDNA release from those cells that EndoIII could not save from propagating further necrosis.

According to the scientists, EndoIII and DNase are the first agents that can both be given at reperfusion and add to the protection of current available treatments, and thus should be effective in today’s patient with acute myocardial infarction.

Syncrosome, a scientific preclinical CRO based in France, also uses mouse models for Myocardial Ischemia for efficacy testing. They monitor Coronary artery ligation, reperfusion, blood pressure, heart rate, planimetry, histology and morphological and functional biomarkers. By combining all these parameters, they can most reliably test for appropriate reaction.

http://link.springer.com/article/10.1007/s00395-014-0459-0

Key words: preclinical CRO, preclinical study, animal model, animal research, myocardial, ischemia, infarction, reperfusion, heart, porcine model, mouse model, inflammation, inflammatory, proinflammatory, isoform, myocardial, acute, rat model

L’article The anti-infarct effect of Endonuclease III in a model of myocardial rat ischemia reperfusion est apparu en premier sur ETAP-LAB.

The Forum will be focused on Neurodegenerative Diseases with a mix of specialist panels and company presentations. It will be the occasion for Syncrosome to discuss our gold standard models on Parkinson’s disease & Motor Symptoms.

Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

Please contact us to organize a 1-2-1 meeting in New-york!

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastrointestinal.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Join Syncrosome team next week at Neuroscience Biopartnering Forum in New-York est apparu en premier sur ETAP-LAB.

from Neurology via xlomafota13 on Inoreader http://ift.tt/1Rhor71
via IFTTT

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model est apparu en premier sur ETAP-LAB.

The last january, all the Syncrosome laboratory an commercial team participated on a 2-day team building event in the French Alpes.

It was an enthusiastic “scientific and sportive” experience for everyone!

After different meetings to exchange on topics like:

• Important scientific and commercial results obtained in 2016,
• Satisfactory points and also what need to be improved in 2017,
• Next in vivo challenges that will be faced in 2017…

We had the chance to follow a Biathlon training that combined cross-country skiing and rifle shooting. It was a great experience and also good moments to share together!

L’article Nordic Day Syncrosome est apparu en premier sur ETAP-LAB.

In many studies in rats, echocardiographic validation of the model has not been performed, and, consequently, there are no data that allow assessment of the degree of contractile failure. In studies of possible cellular dysfunction in heart failure after MI, it is clearly essential to select animals that have a safe diagnosis of CHF.

It is generally acknowledged that left ventricular dilatation occurs mainly after large transmural infarctions. Traditionally, because it reflects preload, left ventricular end diastolic pressure has been used as a main criterion of diagnosis of CHF in rats. However, this technique may cause damage to the aortic valves and affect cardiac performance. Echocardiography is a non-invasive alternative approach that may be used to very CHF diagnosis. Researchers decided to evaluate the postinfarction myocardial function in rats and determined echocardiographic criteria for CHF using high performance echocardiography.

Extensive MI was induced in rats by left coronary occlusion and five weeks later, high-frame rate (∼200 Hz), fully digitized, shallow-focus (10–25 mm), two-dimensional, M-mode and Doppler echocardiography was performed.

Because experiments on papillary muscle strips and isolated cardiomyocytes from CHF rats in overt failure, have shown that shortening velocity is substantially reduced the researchers hypothesized that left ventricular wall shortening velocity may be a valid and reliable criterion for CHF.

Animals were examined for clinical signs of CHF and the researchers looked for the echocardiographic measure that best separated the various clinical signs. That measure became the optimal criterion for distinguishing failing rats from nonfailing and sham-operated rats.

Two type of MI induced responses seemed to be clearly visible, one of which had clinical characteristics of CHF and elevated left ventricular end diastolic pressure. Among the echocardiographic variables, only posterior wall shortening velocity separated the failing and nonfailing responses.

It is therefore possible to obtain by high frame rate echocardiography, high- quality recordings in rats, to distinguish MI rats with CHF due to myocardial dysfunction from those without failure and to perform longitudinal studies on myocardial function.

http://jap.physiology.org/content/89/4/1445#sec-17

Syncrosome, a scientific preclinical CRO based in France, also uses a rat with Chronic coronary ligature to model Heart failure for efficacy testing. They monitor, Doppler echocardiography, Coronary artery ligation, reperfusion, blood pressure, heart rate, planimetry, histology and morphological and functional biomarkers. By combining all these parameters, they can most reliably test for appropriate reaction.

Key words: preclinical CRO, preclinical study, animal model, animal research, myocardial, heart failure, infarction, echocardiography, heart, porcine model, rat model, god model, ventricle, myocardial infarction, Congestive heart failure

L’article Echocardiographic preclinical studies of Congestive heart failure est apparu en premier sur ETAP-LAB.

A systemic inflammation like the one observed in AD patients can be induced by an intraperitoneal injection of lipopolysaccharide (LPS). This injection also induces cognitive impairment in mice. Indeed, researchers observed that upon Intraperitoneal injection of LPS, (250 μg/kg) memory impairment was induced. This was determined using passive avoidance and water maze tests in mice. The repeated injection of LPS (250 μg/kg, 3 or 7 times) resulted in an accumulation of Aβ in the hippocampus and cerebralcortex of mice brains. A substantial increase of apoptotic cells was also found in the hippocampus of LPS treated mice, verifying the relationship between LPS-induced accumulation of Aβ and neuronal cell death. These effects could all be suppressed by an anti-inflammatory agent. However, the underlying mechanisms involved in LPS induced cognitive impairment remain unknown.

To investigate the impact of systemic inflammation on memory impairment and its role in cortical amyloid formation and deposition, researchers induced a systemic inflammation in mice through an intraperitoneal injection of LPS. They then investigated the possible mechanisms of LPS-induced memory impairment, neuro-inflammation and amyloidogenesis in vivo and in vitro using immunohistochemistry, ELISA, behavioural tests and Western blotting.

Following a single injection of LPS, the activities of β and γ-secretase in the cortex and hippocampus increased, whereas, the activity of α-secretase decreased in mice brains. Moreover, LPS treatment increased expression of amyloidogenic proteins APP, BACE and C99 accompanied with the increase of inflammatory proteins iNOS and COX-2 expression. Similar to the in vivo results, in vitro tests showed that the inflammatory stimuli concomitantly increased expression of amyloidogenic proteins and increased the expression of inflammatory proteins in both astrocytes and neuronal cells. These results indicate amyloidogenic pathway could be promoted by neuro-inflammatory stimulation in in vitro and in vivo.

Overall the study showed that systemic inflammatory stimuli elevated amyloidogenesis through activation of β- and γ-secretases accompanied with inhibition of α-secretase which together led to elevated Aβ levels in vivo and in vitro. This co-elevated inflammation and amyloidogenesis resulted in neuronal cell death, and thus memory impairment. The use of an anti-inflammatory agent is however sufficient to inhibit both amylodogenesis and neuro-inflammation which led to recovery effects on the LPS-induced memory impairment. In conclusion, the study suggests that systemic neuro-inflammatory reactions could contribute to the development and/ progression of AD pathology, and anti-inflammatory agent could be useful for the prevention of AD.

https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-5-37

Syncrosome is an Efficacy Characterization CRO that offers relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies. Syncrosome uses LPS-rodent for neuro-inflammation.

key words: Alzheimer’s disease, preclinical CRO, preclinical study, animal model, animal research, dopaminergic neurons, hippocampus, cerebral cortex, neuroprotection, Alzheimer animal model, LPS, drug, LPS pre-clinical, amyloidogenesis, intracellular neurofibrillary tangles, amyloid beta peptide, senile plaques, neuro-inflammation, pathogenesis, cytokines, chemokines, oxygen free radicals, intraperitoneal injection of lipopolysaccharide

L’article Mechanism behind memory impairment caused by LPS neuro-inflammation est apparu en premier sur ETAP-LAB.

January 2017 is a great month for all the Syncrosome Laboratory and Commercial team.

On Sunday 29th of January, all the team will be leaving for the French Alpes on a 2-day Team building experience. Our goal is to summarize Syncrosome’s 2016 life and events to build an effective and even better and more efficient project for 2017.

Every idea and every concept or notion will be heard and we will build upon them. We will discuss our success and what we could improve in 2017. The development plan of our new models will be presented to the team.

This experience will help improve our team efforts, relationships and efficiency. So we can face 2017 united and strong.

We will come out of these two Nordic days, renewed and focussed. Stay tuned for news, it is going to be huge.

Stay tuned to have news next week about these 2 Nordic days.

L’article Syncrosome in French Alpes for a Special Nordic Team Event est apparu en premier sur ETAP-LAB.

Organized in september 2015 in Amsterdam, ERS 2015 European Respiratory Society)  is an international congress on Respiratory diseases, with more than 20 000 attendees! SYNCROSOME was extremely proud to be part of the adventure this year, with a new poster presenting our development on a new  innovative PAH Sugen in vivo model, wich has been accepted at the congress.

Data shows very interesting results concerning several parameters including translationnal biomarkers, histology, hemodynamic and Right Ventricular hypertrophy.

To download the poster:

http://pro.syncrosome.com/941-poster-pah-sugen-ers-2015-syncrosome

L’article Syncrosome: poster Preclinical PAH Sugen – European Respiratory Society meeting est apparu en premier sur ETAP-LAB.

Methods
We studied 30 patients, including 16 well-characterized IPD patients and 14 patients fulfilling PAF diagnostic criteria, and 15 age-matched controls. Subjects underwent skin biopsy from proximal (ie, cervical) and distal (ie, thigh and leg) sites to study small nerve fiber and intraneural n-syn and p-syn.

Results
PAF and IPD showed length-dependent somatic and autonomic small fiber loss, more severely expressed in patients with higher p-syn load. n-syn was similarly expressed in both groups of patients and controls. By contrast, p-syn was not evident in any skin sample of controls but was found in all PAF and IPD patients, although with different skin innervation. In addition, abnormal α-synuclein deposits were found in all analyzed skin samples in PAF but in only 49% of samples with a higher positivity rate at the proximal site in IPD.

Interpretation
(1) Intraneural p-syn was a reliable in vivo marker of PAF and IPD; (2) neuritic p-syn inclusions differed in PAF and IPD, suggesting a different underlying pathogenesis; (3) when searching for abnormal p-syn deposits in skin nerves, the site of analysis is irrelevant in PAF but it is critical in IPD.
Ann Neurol 2015

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Alpha synuclein Parkinson disease and pure autonomic failure in patients est apparu en premier sur ETAP-LAB.

Ulcerative colitis (UC) together with Crohn’s disease (CD), are Inflammatory bowel diseases (mouse IBD). The chronic and relapsing inflammation of all or part of the digestive tract causes severe diarrhea, pain, fatigue and weight loss. Researchers currently believe that a dysregulated immune response to resident intestinal bacteria, influenced by genetic and environmental factors, is responsible for the disruption of the complex immune balance in the bowel environment and the intestinal tissue damage. The diseases are characterized by proinflammatory cytokine production, leukocyte infiltration, and consequent structural and functional damage to the gut.

Today, there is no cure for the diseases but treatments exist to limit the recurrence of the symptoms. Controlled tissue cooling or hypothermia is widely used to suppress tissue damage resulting from trauma, ischemia, and surgery and is known to result in a reduction in inflammation and severity of peripheral nerve injury and could be used to reduce the inflammatory response in colitis. Researchers looked into the mechanisms behind the cooling effect to find the key regulator responsible for the reduction of the inflammation.

Recently, Transient Receptor Potential Melastatin–8 (TRPM8) was identified as a temperature-sensitive ion channel activated by mild cooling and chemical stimuli such as menthol and icilin. Apart from its role in thermosensation, acute activation or inhibition of TRPM8 can have analgesic effects either to diminish neuropathic and visceral pain or to attenuate cold hypersensitivity in inflammatory and nerve-injury pain models. This suggests that neuronal TRPM8 may play a neurogenic anti-inflammatory role in certain settings and also attenuate systemic inflammation.

In two mouse IBD models – 2,4,6-trinitrobenzenesulfonic acid (TNBS) and Dextran Sodium Sulfate (DSS) – of colitis, researchers studied the involvement of TRPM8 in regulating colonic inflammation. Among various chemically induced colitis models, the dextran sulfate sodium (DSS)-induced colitis model is widely used because of its simplicity and many similarities with human ulcerative colitis. Mice are subjected several days to drinking water supplemented with DSS, which seems to be directly toxic to colonic epithelial cells of the basal crypts. Dextran Sodium Sulfate (DSS)-treated TRPM8 knockout mice showed elevated colonic levels of the inflammatory neuropeptide calcitonin-gene–related peptide.

The researchers also found that TRPM8 activation, very likely mediates some of the anti-inflammatory effects of mild cooling for trauma-induced peripheral inflammation, in addition to its neuronal sensory function. They showed that it was also responsible for the attenuation of tissue inflammation in the setting of experimental colitis as TRPM8 mRNA was up regulated in inflamed human and murine colon tissue.

TRPM8 activation had potent anti-inflammatory and disease-attenuating effects that occurred, at least in part, through the suppression of Transient Receptor Potential Vanilloid-1 (TRPV1)-dependent calcitonin-gene–related peptide (CGRP) release in the colon. The anti-inflammatory role for TRPM8 activation, is in part due to an inhibiton of neuropeptide release. In addition to its antinociceptive action, TRPM8 has thus an anti-inflammatory role, and this channel could become a promising therapeutic target for treating inflammatory diseases such as colitis/IBD.

http://journals.plos.org/plosgenetics/article?id=10.1371%2Fjournal.pgen.1006126

Syncrosome is an Efficacy Characterization CRO that offers relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies. Syncrosome uses DSS-rodent for drug screening and efficacy testing for Inflammatory Bowel disease (including Crohn’s disease et Ulcerative colitis).

Key words: preclinical CRO, preclinical study, animal model, disease model, animal research, DSS model, DSS – mouse model, Inflammatory Bowel disease, Crohn’s disease, Ulcerative colitis, gastrointestinal tract, inflammation, immune system, cytokine, interleukine, immunity, bowel, transgenic, cold, channel, analgesic, temperature-sensitive

L’article Novel therapeuthic target against Ulcerative Colitis-Crohn disease in a mouse IBD model est apparu en premier sur ETAP-LAB.

This diversity makes blocking the disease at a receptor level unfeasible; however, inhibition at the subreceptor level is possible if a common signaling element is identified. Phosphoinositide 3-kinase (PI3K) could represent this gatekeeper, specifically the γ and δ isoforms as genetic deletion studies establish their roles in edema and inflammatory responses.
PI3K inhibitors are commonly associated with reduced inflammatory events in animal models but there is also considerable evidence supporting a prosurvival role for during ischemia and, in general PI3K pathways are considered beneficial events that should not be disrupted during I/R injuries. On the whole, it is quite controversial whether inhibition of PI3K signaling would prove beneficial, detrimental, or inconsequential to infarct development.
Researchers tried using a previously undescribed PI3Kγ/δ inhibitor (TG100-115) to interrupt the reperfusion phase of I/R injury. The molecule was confirmed as a potent inhibitor of edema and inflammation induced by both receptors linked to PI3K, but at the same time spared tissue repair processes.

In a mouse ischemia and porcine models, it reduced infarct development and improved myocardial function. Cardioprotection was seen upon delivery up to several hours after reperfusion, an important factor for human care. The data support the hypothesis that broadly blocking proinflammatory processes can limit I/R injury even well after the initiation of ischemic damage.
Based on the results of this study, the researchers believe that selective PI3K isoform inhibition holds promise for bridging that gap between preclinical efficacy and clinical utility.

Syncrosome, a scientific preclinical CRO based in France, also uses mouse ischemia models for Myocardial Ischemia for efficacy testing. They monitor Coronary artery ligation, reperfusion, blood pressure, heart rate, planimetry, histology and morphological and functional biomarkers. By combining all these parameters, they can most reliably test for appropriate reaction.

http://www.pnas.org/content/103/52/19866.full

Key words: preclinical CRO, preclinical study, animal model, animal research, myocardial, ischemia, infarction, reperfusion, heart, porcine model, mouse model, inflammation, inflammatory, proinflammatory, isoform.

L’article Mouse ischemia reperfusion: a good preclinical model for myocardial infarction? est apparu en premier sur ETAP-LAB.

For more than 6 years now, Syncrosome has worked as a preclinical CRO accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR).

Our recognition procures a significant financial benefit for French companies wishing to pursue their R & D work in Cardiovascular, Central Nervous System, Respiratory or Gastrointestinal field with Syncrosome.
This authorization is accorded for the years 2015 to 2019.

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastrointestinal.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article SYNCROSOME CIR accreditation est apparu en premier sur ETAP-LAB.

However, the disease isn’t only restricted to the bowel and extraintestinal manifestations and complications are common in patients with inflammatory bowel disease (IBD) and can involve almost any organ or system. Indeed, inflammatory mediators can cause distant organ injury in many disease models. Previous studies have suggested the presence of an association between UC and kidney injury, but whether UC and kidney injury can be suppressed with anti-inflammatory therapy have never been examined.

The researchers examined the effect of dextran sulfate sodium (DSS)-induced colitis, with symptoms similar to human ulcerative colitis, on kidney injury and inflammation. In addition, they hypothesized that netrin-1, a guidance cue shown to have anti-apoptotic and anti-inflammatory functions in many models of acute and chronic diseases, could modulate colon-kidney cross talk through regulation of inflammation and apoptosis.

DSS induced colitis did indeed induced acute kidney injury in mice and overexpression of netrin-1 in epithelial cells reversed the effects and both suppressed colitis and colitis-induced acute kidney injury. Netrin-1’s protective effects were mediated through suppression of IL-6 as IL-6 knockout mice were resistant to colitis and acute kidney injury. Netrin-1 may reduce both IL-6 production and activity.

The researchers thus identified previously unrecognized cross talk between the colon and kidney. This is the first report that epithelial-specific overexpression of netrin-1 can suppress DSS induced colitis, inflammation, and acute kidney injury. Netrin-1 may limit distant organ injury by suppressing inflammatory mediators such as IL-6 and apoptosis. Overall, the study suggests that organ cross talk in DSS-induced colitis can be effectively treated with the anti-inflammatory molecule netrin-1.

http://ajprenal.physiology.org/content/304/9/F1187.abstract

Syncrosome is an Efficacy Characterization CRO that offers relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies. Syncrosome uses DSS-rodent for drug screening and efficacy testing for Inflammatory Bowel disease (including Crohn’s disease et Ulcerative colitis).

Key words: preclinical CRO, preclinical study, animal model, disease model, animal research, DSS model, DSS – mouse model, Inflammatory Bowel disease, Crohn’s disease, Ulcerative colitis, gastrointestinal tract, inflammation, immune system, kidney, organ cross talk, efficacy testing, drug screening

L’article Organ cross talk in DSS induced colitis can be effectively treated with anti-inflammatory molecule est apparu en premier sur ETAP-LAB.

Figure : RVSP and mass ratio (right ventricle/left ventricle + septum) differences between Sugen/hypoxia and Vehicle/Normoxia mice.

On the other hand, since several years, Syncrosome propose three different preclinical rat models of PAH (chronic hypoxia exposure, monocrotaline-induced and Sugen/hypoxia-induced models). Our rat and mouse preclinical models of PAH allow drug discovery companies to perform preclinical efficacy studies according to their needs.

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO offering relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.We have developed and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers. Our main activities include :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic diseases,
  • Respiratory System,
  • Early bioavailability and CNS-PK on rodents and non-rodents, with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome sets up a new preclinical PAH (Pulmonary Arterial Hypertension) model in mouse. est apparu en premier sur ETAP-LAB.

In the framework of our development, we are proud to announce the recruitment of our new scientific colleague, Guénaelle CANET. She will work in our Technical Department at the Lab and will be in charge, with the scientific and technical team, of setting up different in vivo Efficacy disease models in reproducible conditions.

Guénaëlle acquired two master degrees in Neurosciences and Preclinical Research from Claude Bernard University of Lyon. These formations allowed her both develop robust knowledge in Neurosciences and obtain in vivo skills in preclinical study. She will rapidly be able to realize in vivo preclinical studies alone in Cardiovascular, Central Nervous System, Respiratory and Gastrointestinal field in a GLP-Like environment and of course give us her vision and new indications to keep update!

After her six months internship in SYNCROSOME, during which she mainly participated in Gastroenterology and Central Nervous System R&D projects, she integrated our team in order to ensure the technical proceedings and complete our in vivo skills.

Guénaëlle and all the Syncrosome team will be happy to respond to all your requests, questions or comments!

You can contact us via our mail: dvpt@syncrosome.com

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastroenterology.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Syncrosome keeps increasing its In vivo Preclinical skills est apparu en premier sur ETAP-LAB.

Researchers from the college of Pharmaceutical Sciences  in China have recently studied a compound that enhances neuronal recovery in a rat model of Parkinson’s disease (Parkinson 6 OHDA). Parkinson’s disease is a chronic disorder of the central nervous system, caused primarily by the progressive loss of dopaminergic neurons of the Substantia nigra region of the brain that play an important role in reward, addiction and movement.

The researchers administered intranasally phospholipid-based gelatin nanoparticules loaded with neuropeptide Substance P to rat models of Parkinson’s disease and monitored the rotational behaviour of the animals, as well as their levels of tyrosine hydroxylase, phosphorylated c-Jun protein and Caspase-3 expressed in their substantia nigra. This Neuropeptide Substance P (SP) is involved in the regulation of many biological processes and is a major mediator of neuroimmunomodulatory activities and neurogenic inflammation. In vitro experiments had already shown that SP can protect dopamine neurons from toxicity, decrease neuron apoptosis and enhance cell growth.

In Parkinson’s disease patients, the expression of SP and dopamine is significantly reduced in the Substantia Nigra, which results in an increase death of dopaminergic neurons and a limited expression of tyrosine hydroxylase. The researchers chose to use hemiparkinsonian rats with a substantia nigra partially damaged by 6-OHDA to model Parkinson’s disease. 6-OHDA injections into the brains of rats induce apoptosis of dopaminergic neurons and reduce the expression of SP – mimicking the symptoms of Parkinson’s disease. The 6-OHDA model is a valuable tool frequently used in rodents, mostly to investigate motor and biochemical dysfunctions in Parkinson’s disease. It mimics the human situation closely and has the advantage of presenting side-biased motor impairments and being very sensitive to dopamine agonists. More subtle models of partial dopaminergic degeneration have been developed to reveal finer motor deficits but the 6-OHDA model remains the traditional model for testing Parkinson’s therapies, especially those intended to increase dopamine levels in the striatum.

SP plays an important role in the recovery of diseased dopaminergic neuron through the deactivation of the JNK pathway – one of the important pathways leading to dopamine neuronal apoptosis in the Substantia negra – and decrease in neuronal apoptosis. However, as a macromolecule, it is not likely that SP administrated orally or intravenously could cross the blood-brain barrier. The current study investigated whether SP can be delivered into the CNS intranasally thanks to gelatin nanoparticles to play a neuroprotective role by inhibiting activation of JNK pathway and decrease dopaminergic neuron apoptosis.

This preclinical study found that SP can be effectively delivered into the damaged Substantia negra region through the nose-to-brain pathway and efficiently inhibit dopaminergic neuron apoptosis through the JNK pathway, allowing for hemiparkinsonian rats to recover.

This study will hopefully lead to clinical trial to help the 1-2% of the population above the age of 60 affected by Parkinson’s disease that remains a difficult disease for clinical management.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148848&__scoop_post=d6f941e0-d8e8-11e5-927b-00221934899c&__scoop_topic=3284569#__scoop_post=d6f941e0-d8e8-11e5-927b-00221934899c&__scoop_topic=3284569

Syncrosome is an Efficacy Characterization preclinical CRO that offers relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies. Syncrosome is specialized in Parkison preclinical evaluation and uses 2 differents 6-OHDA rodent models (early and late stage), for drug screening and efficacy testing. Other Parkinson models also available.

Key words: Parkinson preclinical, preclinical CRO, preclinical study, animal model, dyskinesia rat, 6-OHDA rat,  rodent dopaminergic neurons, Substantia nigra, neuroprotection, blood brain barrier, Parkinson animal model, MPTP, MPP+

L’article Parkinson 6 OHDA preclinical: New POC on rat to repair neurons, with new compound. est apparu en premier sur ETAP-LAB.

As rodents do not possess an emetic reflex, it is not possible to directly investigate the role of different isoforms of PDE4 in preclinical emesis, however, a surrogate biological response can be observed as a measure of an emetic response: the reversal of anaesthesia induced by α2-adrenoceptor agonists. The role of this alternative biological response was assessed in ferrets, the usual model to study emesis because it has an emetic reflex. Pre-treatment with different α2-adrenoceptor antagonists caused sudden and unexpected vomiting in ferrets whereas α2-adrenoceptor agonist did not induce emesis at doses ranging from 62.5–250 μg/kg s.c.

At higher doses (250 μg/kg), it was also shown that α2-adrenoceptor agonist could also have a protective role in ferrets against emesis induced by the PDE4 inhibitors. It was postulated that PDE4 inhibitors trigger emesis by mimicking the pharmacological actions of α2-adrenoceptor antagonists by raising cyclic AMP within central noradrenergic terminals. Indeed, PDE4 inhibitors and different different α2-adrenoceptor antagonists can also reverse the hypnotic effect of α2-adrenoceptor induced anaesthesia.

These studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compounds trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacological actions of a pre-synaptic α2-adrenoceptor inhibition. In other animal models, the emetic reflex of PDE4 inhibitors could be studied by looking at a surrogate biological response, a reversal of anaesthesia induced by α2-adrenoceptor agonists

http://www.sciencedirect.com/science/article/pii/S0028390800001428

Syncrosome is an Efficacy Characterization CRO that offers relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies. Syncrosome uses ferret models and porcine models for emesis testing of drugs.

Key words: preclinical CRO, preclinical study, animal model, disease model, animal research, efficacy testing, drug screening, nausea, emesis, emetic, noradrenergic, PDE4, PDE5, ferret, porcine, pig.

L’article Evaluating preclinical emesis induced by PDE4 inhibitors via a noradrenergic pathway est apparu en premier sur ETAP-LAB.

Syncrosome invites you to visit us at Bio-Europe, November 7th to November 9th 2016, in Cologne, Germany.

Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects.

We can give you advice about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.

Please contact us to organize a 1-2-1 meeting in Cologne!

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastrointestinal.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article Join Syncrosome team at Bio-Europe in Cologne, Germany, next week! est apparu en premier sur ETAP-LAB.

Hi Europe &Ni promises you a complete 360 degree perspective of the nutrition and health ingredients industry through an exclusive offering of new ingredients & solutions, innovative tours, presentations & live demonstrations.

We are in Frankfurt from 29 November – 1 December and would like to invite you to our booth!

WE’LL BE WAITING FOR YOU
AT STAND F48-5

We will showcase our latest innovations and our team will be ready to meet you face-to-face..

We look forward to seeing you in Frankfurt!

L’article Join ETAP-Lab at Hi Europe & Ni est apparu en premier sur ETAP-LAB.

Syncrosome is happy to host a booth and participate to the networking event.

Syncrosome provides a complete service in Preclinical Efficacy testing from in vitro to in vivo testing and trough biodisponibility studies on rodents and non-rodents species. Our multiple skills, combined with scientific background and 15 years of expertize results in fruitful collaboration with Pharmaceutical and Biotech. Companies.

Come on our booth and visit us

• Meet Emmanuelle, your Business contact at Syncrosome since 2009
• Discover our new in vitro and vivo models
• Discuss your preclinical project with experts and save time on your project

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome at the 2nd DDIP in Munich est apparu en premier sur ETAP-LAB.

It was 2 very interesting days spent to discuss about the new advances in Imaging of Neurodegeneration, Alzheimer and Parkinson’s Disease and Drug Discovery, New trends in Preclinical animal models and Neuroimaging….

Our Scientific representative, Sandra Robelet, launched a talk on the new preclinical strategy combining in vitro and in vivo models to assess the drug efficacy of your compounds in Neurodegenerative disease and interacted with Pharma and Biotech’s companies from all around the world. This talk has been very appreciated from the audience due to the continuation between in vitro and in vivo strategies in Parkinson disease.

An other interesting point discussed, was the CNS-PK tools (CSF sampling and Microdialysis with the monitoring of Neurotransmitters) that could complete the response of in vitro and in vivo disease models with a biochemical approaches of the disease.

Contact us if you want to read the presentation or discuss with us directly!

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

L’article BACK from the 2nd Annual Neuroscience R&D Technologies Conference est apparu en premier sur ETAP-LAB.

These AIMs are induced in our rat model of PD (unilateral 6-OHDA lesion) after a chronic administration of L-DOPA during several weeks. 3 types of AIMs are scored: orolingual, limb and axial during several hours and each AIM are scored separately.

Until now, a rating scale based only on the duration of each AIM was used. However the measurement of only the duration of behaviours was considered a limitation. A more expansive version of this scale was set up with the addition of amplitude parameter for each AIM improving sensitivity to the effects of our antidyskinetic reference compound, amantadine as well as a candidate compound.

This new rating scale of AIM allows us to propose a more pertinent model to evaluate the antidyskinetic potential effect of candidate compounds.

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

• Drug Efficacy Studies in several therapeutic areas :
  • Central Nervous Sytem,
  • Cardiovascular and Metabolic disease,
  • Respiratory.
• Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage

L’article NEW RATING SCALE OF AIMs IN OUR L-DOPA INDUCED DYSKINESIAS RAT MODEL est apparu en premier sur ETAP-LAB.

ETAP-Lab’s preclinical results obtained for PiLeJe will be presented in a poster “Identification of two probiotic strains able to prevent skin inflammation in a murine model” at the 4^th World Congress on Targeting Microbiota, October 17-19, 2016, Institut Pasteur, Paris (France).

Congress Website

PiLeJe Website

L’article Poster presentation at the 4th World Congress on Targeting Microbiota est apparu en premier sur ETAP-LAB.

Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease models, and more specifically Parkinson Disease (PD).

This department is also focused on CNS-PK with relevant tools as microdialysis and CSF sampling.

I am pleased to inform you that Syncrosome will attend the 2^nd Annual Neuroscience R&D Technologies Conference, in London, UK on September 29 – 30, 2016.

During the congress, Sandra Robelet, Scientific Manager in Syncrosome, will make a speech on “ Preclinical strategy combining in vitro and in vivo models to assess drug efficacy in Neurodegenerative disease”. This conference is scheduled the 29^th of September in the morning.

Hereafter you will find some conference’s topics:

• Target identification & Validation technologies : Human pluripotent stem cells to model and treat Parkinson’s disease…
• Translational imaging : The imaging of Neurodegeneration…
• Neuroinformatics & Computational Neurosciences…
• Advances in Animal models…

Come on our booth and visit us

• Meet our Head of Central Nervous System department
• Discover our new in vitro and vivo models
• Discuss your preclinical project with experts and save time on your project
• Find out why our cutting-edge services might be the solutions for your CNS drug development

Looking forward to seeing you soon,

Give a look to our website.

Syncrosome team

To schedule a meeting with Syncrosome representatives, please email Emmanuelle Bettendorf, your preferred preclinical CRO contact!

L’article Syncrosome & the 2nd Annual Neuroscience Conference. est apparu en premier sur ETAP-LAB.

Stroke is one of the most prevalent life-threatening conditions in western countries. As an emergency condition, it is the second most common cause of death, as well as the leading cause of acquired handicap, worldwide – resulting in high socio-economic impact. Around 80-87% of strokes are ischemic. Ischemia is commonly induced by a clot (thrombus) either generated within brain vessels or moved by arterial blood flow (i.e. embolism) toward the brain, resulting in the occlusion of a cerebral artery. Hypoperfused brain tissue is then quickly injured, depending on remaining local blood flow – yet can be salvaged if reperfusion occurs within minutes or hours. Rapid and complete reperfusion following stroke onset will maximize ischemic cerebral tissue salvation.

Reperfusion can be achieved through pharmacological intervention using fibrinolytic drugs capable of dissolving thrombi. Alteplase is currently the only fibrinolytic drug approved for the treatment of acute ischemic stroke. This treatment does however have significant limitations: a short therapeutic window (a maximum of 4 to 6 hours after stroke onset), increased risk of cerebral haemorrhage, poor efficacy in about 70% of patients and potential neurotoxicity. New treatments are thus urgently needed.

The ETAP-Lab thrombo-embolic stroke model in rats allows testing of new fibrinolytic and profibrinolytic drugs. Stroke is induced by injection of multiple autologous blood clots toward the middle cerebral artery. Stroke intensity can be customized to produce lacunar lesions to extended cerebral injury. Alteplase resistance is achieved in the extended cerebral injury version, allowing testing of drugs designed to potentiate Alteplase treatment. Neuroprotective strategies can also be tested in the presence of Alteplase, in combined-treatment experimental designs. Efficacy is evaluated via an original neuroscore and histological analysis.

MRI in vivo studies empowers stroke studies by direct and repeated measurement of lesion volumes. Angiography and local cerebral blood flow measurement provide important data concerning the efficacy of the tested drugs. MRI also provides access to endpoints such as haemorrhagic volumes, haemato-encephalic barrier permeability and neuro-inflammation. The combination of MIRCen expertise with an 11.7 Tesla MRI device ensures first-class imaging quality and data interpretation.

Contact us to know more about ETAP-Lab’s stroke model.

Contact us

Link to MIRCen Website:

L’article ETAP-Lab associates with MIRCen to perform a MRI translationnal study in stroke est apparu en premier sur ETAP-LAB.

CEN Nutriment and ETAP-Lab are pleased to announce they go into partnership to propose a global advice and service offer aimed at allowing their clients to meet EFSA requirement regarding scientific files for Health-Claims.

ETAP-Lab proposes a large scale of preclinical trials to assess the safety and efficacy of products with potential health benefits. CEN Nutriment attains the next milestone by developing and performing clinical trial and observational studies to evaluate health claims of these products. The complementary experience shared by both societies allows to elaborate a consistent R&D program for your product, from proof of concept to clinical validation, aiming for health claim.

Contact us to know more about the offer

Contact us

L’article From preclinic to clinic: CEN Nutriment and ETAP-Lab new partnership for a global offer to health-nutrition R&D est apparu en premier sur ETAP-LAB.

L’article New contracts on toxicology signed this month est apparu en premier sur ETAP-LAB.

L’article New article co-written by ETAP-Lab published in Journal of Medicinal Food. est apparu en premier sur ETAP-LAB.

L’article New article co-written by ETAP-Lab accepted by Journal of Medicinal Food est apparu en premier sur ETAP-LAB.

Visit our Stand: ETAP-Lab / CEN Nutriment.

L’article ETAP-Lab will participate to the 11th edition of JAS on June 15 & 16 in La Rochelle (France), represented by Pascale ROZAN and Jean-François BISSON est apparu en premier sur ETAP-LAB.

Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed. Vaccination has positioned itself as a prime strategy for addressing these diseases because it is broadly applicable, requires infrequent administration, and maintains low production costs for treating a large population or as a preventive measure. Current evidence points to a causal role of misfolded α-synuclein in the development and progression of synucleinopathies. In the past decade, significant progress in active immunization against α-synuclein has been shown both in preclinical animal models and in early clinical development. In this review, we describe the state-of-the-art in active immunization approaches to synucleinopathies, with a focus on advances in Parkinson’s disease (PD) and multiple-system atrophy (MSA). We first review preclinical animal models (synuclein and Parkinson), highlighting their progress in translation to the clinical setting. We then discuss current clinical applications, stressing different approaches taken to address α-synuclein pathology. Finally, we address challenges, trends, and future perspectives of current vaccination programs. © 2015 International Parkinson and Movement Disorder Society

© 2015 International Parkinson and Movement Disorder Society

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy est apparu en premier sur ETAP-LAB.

http://www.ncbi.nlm.nih.gov/pubmed/26260853

L’article Synucleopathies and preclinical Parkinson disease models est apparu en premier sur ETAP-LAB.

Researchers from the CHU Research centre in Quebec have shown that diet can play a neuroprotective role in a preclinical Parkinson mouse model. They investigated the effects of a omega-3 polyunsaturated fatty acids-enriched diet, in the form of docosahexaenoic acid (DHA), on damaged neurons. C57BL/6 adult mice were injected in the Substantia nigra with 6-OHDA ( 6 OHDA Parkinson) to induce dopaminergic denervation and cell loss, to mimic the symptoms of Parkinson’s disease. The 6-OHDA model is a valuable tool frequently used in rodents, mostly to investigate motor and biochemical dysfunctions in Parkinson’s disease. A group of 6-OHDA mice were fed a omage-3 rich diet for 6 weeks and the researchers found that these mice had 52% more dopamine in their striatum than control 6-OHDA mice and a 47% rise in tyrosine-hydroxylase, an enzyme involved in the production of dopamime, although no improvement in their motor behavior was observed. Morphological data showed no increase in the number of dopaminergic cell bodies in treated animals but did show an increase in perimeters (+6%) and areas (+17%). Overall, the scientists showed using a preclinical Parkinson model usually used to assess dyskinesia, that an omega-3 enriched diet can induce a partial neurorestoration of the dopaminergic system. Syncrosome, a scientific preclinical CRO based in France, also uses the Parkinson preclinical 6-OHDA model to monitor the neuroprotective properties of compounds in preclinical trials (early and late stage of the Parkinson disease are possible), and also dyskinesia-akinesia for efficacy testing. We think that these 6 OHDA Parkinson preclinical disease models are more relevant than MPTP or MPP+ induction.

http://dx.doi.org/10.1016/j.jnutbio.2015.11.014

L’article Neuroprotective effects of Omega-3 on 6 OHDA Parkinson preclinical mice. est apparu en premier sur ETAP-LAB.

L’article New article co-written by ETAP-Lab published in Journal of Functional Foods est apparu en premier sur ETAP-LAB.

Results are reproducible and shows a vascular remodeling, increased Right Ventricular Systolic Pressure and a Right Ventricular Hypertrophy. These results strongly support this preclinical rat PAH Sugen model to be used for the preclinical evaluation of drug candidates for the treatment of human PAH.

2015-Poster-PAH-Sugen-ERS-2015-Syncrosome-

L’article Poster PAH sugen – ERS meeting est apparu en premier sur ETAP-LAB.

L’article Syncrosome Poster 6 OHDA Parkinson and dyskinesia est apparu en premier sur ETAP-LAB.

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS synuclein Parkinson, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy est apparu en premier sur ETAP-LAB.

L’article Neurorescue and DHA on a 6OHDA preclinical Parkinson model est apparu en premier sur ETAP-LAB.

About the Article:
Recasens A and Dehay B (2014) Alpha-synuclein spreading in Parkinson’s disease. Front. Neuroanat. 8:159.

About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

L’article Alpha-synuclein in Parkinson disease est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article Participation of ETAP-Lab to the FIE 2015 in Paris. est apparu en premier sur ETAP-LAB.

L’article New article co-written by ETAP-Lab accepted for publication in Neurotoxicology est apparu en premier sur ETAP-LAB.

L’article New article co-written by ETAP-Lab published in PRIME International Journal of Aesthetic and Anti-Ageing Medicine est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to BIOFIT 2015 on December 1st & 2nd in Strasbourg (France), represented by Nicolas VIOLLE (CEO) and Jean-François BISSON (Scientific Director) est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to NutrEvent 2015 on June 17 & 18 in Lille (France), represented by Pascale ROZAN and Jean-François BISSON est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to the Health Ingredients Europe and Natural Ingredients 2014 (HIE & NI 2014) meeting on December 2 and 3 in Amsterdam, represented by Jean-François BISSON, Scientific Director of ETAP est apparu en premier sur ETAP-LAB.

For more information about this meeting click here.

L’article ETAP will participate to InsectInov on December 2 and 3 in Paris, represented by Pascale ROZAN est apparu en premier sur ETAP-LAB.

You can meet Jean-François BISSON (Scientific Director ETAP and ISCHOM Secretary) for any inquiry about the activities of ETAP and experimental models available for your research.

For more information about this congress click here.

L’article ETAP is co-organizing the First International Congress on Chocolate and Cocoa in Medicine that will be held in Florence (Italy) on September 26 to 27, 2014, represented by Jean-François BISSON est apparu en premier sur ETAP-LAB.

L’article ETAP will be present to the 10th edition of the Journées Aliments-Santé (Food – Health Days) on June 18th and 19th 2014 in La Rochelle (FRANCE) – represented by Pascale ROZAN and Jean-François BISSON est apparu en premier sur ETAP-LAB.

For more information about this congress click here.

L’article ETAP will be present to the VITAFOODS Europe 2014 in Geneva (Switzerland) on May 6 and 7 – represented by Jean-François BISSON (Scientific Director) est apparu en premier sur ETAP-LAB.

L’article DERMATOLOGY – ETAP’s research works in the French journal for Physician: Wound healing and Chlorella microalgae est apparu en premier sur ETAP-LAB.

For more information about this congress click here.

L’article ETAP will be present at the 20th world congress on Parkinson’s disease and related disorders – represented by C. MULLER est apparu en premier sur ETAP-LAB.

You can meet Dr N. Violle to talk about the activities of ETAP.

For more information about this congres click here.

L’article ETAP will be present at the Zoopsy congres focused on psychoactive drugs est apparu en premier sur ETAP-LAB.

For more information about this forum click here.

L’article ETAP will be present at the Forum Atlanpole Blue Cluster – represented by P. ROZAN est apparu en premier sur ETAP-LAB.

For more information about this symposium click here

L’article ETAP will be present at the 39th sympasium of AFSTAL – represented by S. HIDALGO est apparu en premier sur ETAP-LAB.